[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2003066830A2 - Anticorps monoclonaux humains diriges contre des proteines membranaires - Google Patents

Anticorps monoclonaux humains diriges contre des proteines membranaires Download PDF

Info

Publication number
WO2003066830A2
WO2003066830A2 PCT/US2003/003763 US0303763W WO03066830A2 WO 2003066830 A2 WO2003066830 A2 WO 2003066830A2 US 0303763 W US0303763 W US 0303763W WO 03066830 A2 WO03066830 A2 WO 03066830A2
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
protein
library
receptor
receptors
Prior art date
Application number
PCT/US2003/003763
Other languages
English (en)
Other versions
WO2003066830A3 (fr
Inventor
Shaobing Hua
Michelle H. Pauling
Li Zhu
Original Assignee
Genetastix Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/071,866 external-priority patent/US20030165988A1/en
Priority claimed from US10/072,031 external-priority patent/US6766082B2/en
Application filed by Genetastix Corporation filed Critical Genetastix Corporation
Priority to AU2003209059A priority Critical patent/AU2003209059A1/en
Publication of WO2003066830A2 publication Critical patent/WO2003066830A2/fr
Publication of WO2003066830A3 publication Critical patent/WO2003066830A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Definitions

  • This invention relates to methods for generating monoclonal antibody against cell membrane proteins, and, more particularly, to methods for generating human monoclonal antibodies against cell surface coreceptors for human immunodeficiency virus (HIV) and using these antibodies for diagnostic or therapeutic purposes.
  • HIV human immunodeficiency virus
  • HIV infection has been implicated as the primary cause of the slowly degenerate disease of the immune system termed acquired immune deficiency syndrome (AIDS).
  • AIDS acquired immune deficiency syndrome
  • Infection of the CD4+ subclass of T- lymphocytes with the HIV-1 virus leads to depletion of this essential lymphocyte subclass which inevitably leads to opportunistic infections, neurological disease, neoplastic growth and eventually death.
  • HIV-1 infection and HIV-1 associated diseases represent a major health problem and considerable attention is currently being directed towards the successful design of effective therapeutics.
  • HIV-1 is a member of the lentivirus family of refroviruses. Teich et al. (1984) In RNA Tumor Viruses ed. R. Weiss, N. Teich, H. Varmus, J. Coffin CSH
  • the life cycle of HIV-1 is characterized by a period of proviral latency followed by active replication of the virus.
  • the primary cellular target for the infectious HIV-1 virus is the CD4 subset of human T-lymphocytes. Targeting of the virus to the CD4 subset of cells is due to the fact that the CD4 cell surface protein acts as the cellular receptor for the HIV-1 virus. Dalgleish et al.
  • the HIV-1 virion After binding to the cell surface, the HIV-1 virion becomes internalized, and once inside the cell, the viral life cycle begins by conversion of the RNA genome into linear DNA molecules. This process is dependent on the action of the virally encoded reverse transcriptase. Following replication of the viral genome, the linear DNA molecule integrates into the host genome through the action of the viral integrase protein, thus establishing the proviral form of HIV-1.
  • HIV-1 utilizes several cell membrane proteins as its coreceptor to falitate viral entry into the host cell. Alkhatib et al. (1996) Science 272: 1955-1958; and Deng et al. (1996) Nature
  • chemokine receptors examples include CXCR4, CCR5, CCR1 , CCR2b, CCR3, CCR4, CCR8, CXCR1 , CXCR2, CXCR3, and CX3CRI
  • chemokine receptor-like orphan proteins examples include STRL33/BONZO and GPR15/BOB.
  • CXCR4 also known as "fusin" is a receptor for chemokines such as
  • CCR5 is a receptor for several CC chemokines such as MlP-1 ⁇ (also named GOS19, LD78, pAT464 gene product, TY5 (murine) and SIS ⁇ (murine)), MIP-1 ⁇ (also named Act-2, G-26, pAT744 gene product, H-400 (murine) and hSIS ⁇ (murine)) and RANTES (regulated on activation, normal T cell expressed and secreted, or CCL ⁇ ).
  • MlP-1 ⁇ also named GOS19, LD78, pAT464 gene product, TY5 (murine) and SIS ⁇ (murine)
  • MIP-1 ⁇ also named Act-2, G-26, pAT744 gene product, H-400 (murine) and hSIS ⁇ (murine)
  • RANTES regulated on activation, normal T cell expressed and secreted, or CCL ⁇
  • Macrophages-tropic (M-tropic) strains of HIV virus can replicate in primary CD4 + T cells and macrophages and use the ⁇ -chemokine receptor CCR5 and less often, CCR3 receptor.
  • T cell line-tropic (T-tropic) HIV strains can also replicate in primary CD4 + T cells but can in addition infect established CD4 + T cell lines in vitro via the ⁇ -chemokine receptor CXCR4. Many of the T-tropic strains can use CCR5 in addition to CXCR4.
  • Chemokine receptor-like HIV coreceptor STRL33 is expressed in activated peripheral blood lymphocytes and T-cell lines and can function as an entry cofactor for Env proteins from M-tropic, T-tropic and dual tropic strains of HIV-1 and SIV.
  • HIV coreceptors have also been identified by numerous in vitro assays, including chemokine receptors CCR2b, CCR3, CCR8 and CX3CR1 as well as several chemokine receptor-like orphan receptor proteins such as GPR15/BOB and STRL33/BONZO. Each or a set of these HIV coreceptors can mediate entry of different strains of HIV virus into the host cell.
  • the CC chemokine receptor CCR5 is a principal HIV-1 coreceptor that plays a dominant role in disease transmission and in the early course of infection. Berger et al. (1999) Annu. Rev. Immunol. 17:657-700. Molecular epidemiology studies clearly demonstrated that CCR5 plays critical roles in HIV-
  • CCR5 provides an attractive target for new antiretroviral therapies. Liu et al. (1996) Cell 86:367-377; and Michael & Moore (1999) Nat. Med. 5:740-742.
  • Several approaches have been employed to target HIV coreceptors, involving proteins, peptides and small molecules. It has been found that some CCR5-targeting chemokines and chemokine analogs are capable of inhibiting HIV-1 replication in vitro. Berger et al. (1999) Annu. Rev. Immunol. 17:657-700.
  • RANTES possesses significantly greater breadth of antiviral activity than MIP-1 ⁇ and MIP-1 ⁇ , although all CC chemokines show interisolate variation in potency. Trkola et al. (1998) J. Viol. 72:396-404.
  • the antiviral activity of the CC chemokines better correlates with their ability to downregulate rather than to bind CCR5 on CD4 T cells, and sustained down-regulation of CCR5 has been suggested to be a principal mechanism of action for the chemokine analog aminooxypentane (AOP)-
  • AOP chemokine analog aminooxypentane
  • TAK-779 A small non- peptide molecule designated TAK-779 was found to be an antagonist against CCR5 presumably through binding to a hydrophobic pocket defined by the transmembrane helices 1 , 2, 3 and 7.
  • Phage display has been utilized to select for single chain antibody against CCR5 from a human antibody library by using CCR5-expressing CD4 + lymphocytes as the target in the presence and absence of MIP-1 .
  • Osbourn et al. (1998) Nature Biotech. 16:778-781.
  • the selected phage particles were analyzed by phage ELISA for their ability to recognize CD4 + lymphocytes, CCR5- transfected CHO cell line, non-transfected CHO cell line, and a BSA-conjugated peptide corresponding to the N-terminal 20 amino acid peptide of CCR5.
  • CD4 + lymphocytes as well as MIP-1 ⁇ -mediated calcium signaling.
  • Mouse monoclonal antibodies have also been generated to target CCR5 by using the whole protein of CCR5 as the antigen.
  • Wu et al. immunized mice with the murine pre-B cell lymphoma cell line L1.2 expressing high levels of transfected CCR5, which generated a lgG1 monoclonal antibody, designated as mAb 2D7. Wu et al. (1997) J. Exp. Med. 186:1373-1381.
  • the binding site of this monoclonal on CCR5 was mapped to the second extracellular loop of CCR5.
  • MAb 2D7 was shown to be able block the binding and chemotaxis of the three natural chemokine ligands of CCR5, RANTES, macrophage inflammatory protein MIP-1 ⁇ , and MIP-1 ⁇ , to CCR5 transfectants.
  • MAb 2D7 failed to stimulate an increase in intracellular calcium concentration in the CCR5 transfectants, but blocked calcium response elicited by RANTES, MIP-1 ⁇ and MIP-1 ⁇ chemotactic responses of activated T cells, but not of monocyte. In contrast, a group of mAbs that were also generated in the same process and failed to clock chemokine binding were all mapped to the N- terminal region of CCR5.
  • Olson et al. isolated 6 anti- CCR5 murine monoclonal antibodies (MAbs) by intraperitoneally immunizing female BALB/c mice with murine L1.2 cells expressing CCR5. Olson et al. (1999) J. Virol. 73:4145-4155. Epitope mapping of these MAbs reveals that the epitopes of these antibodies reside in the N-terminus and/or second extracellular loop regions of CCR5. This structural information was correlated with the antibodies' abilities to inhibit (1) HIV-1 entry; (2) HIV-1 envelope glycoprotein-mediated membrane fusion; (3) gp120 binding to CCR5; and (4) CC-chemokine acitvity.
  • each of the antibodies displayed distinctly different activities in different stages of HIV-1 entry.
  • one of these MAbs, PRO140 was shown to exert inhibitory effects on HIV-1 infection on primary peripheral blood mononuclear cells (PBMC). Trkola et al. (2001) J. Virol, 75:579-588.
  • the present invention provides innovative methods for generating antibodies against a wide variety of proteins targets, especially against membrane proteins.
  • methods are provided for eliciting monoclonal antibody against a target membrane protein by using a fusion protein as an immunogen that contains a peptide fragment derived from the membrane protein.
  • efficient high through methods are provided for screening fully human antibody library against membrane proteins such as HIV coreceptors in yeast.
  • a method for eliciting antibodies against a membrane protein in a non-human animal.
  • the method comprises: immunizing a non-human animal with an antigen that is a fusion protein between a peptide fragment of a target membrane protein and a heterologous chaperon protein that stabilizes the peptide fragment.
  • the step of immunizing the animal may include injecting the antigen directly into the animal.
  • the antigen may be injected into a mouse to elicit polyclonal antibodies, or monoclonal antibodies by using a hybridoma technology.
  • the animal may be a natural animal, a transgenic animal that has been genetically modified to produce human antibodies, such as
  • XENOMOUSE® and HuMab Mouse or a transchromosome (TC) mouse.
  • the step of immunizing the animal may include transfecting the animal with an expression vector encoding the antigen.
  • DNA sequence encoding the antigen can be inserted into a mammalian expression vector or a viral vector (e.g., retroviral, adenoviral, and adeno-associated viral vectors) and the resulting expression vector can be injected into the animal where the expression of the antigen by the vector elicits immune responses to the antigen.
  • Antibodies can then be isolated from the serum of the animal and used to target the membrane protein for therapeutic or diagnostic purposes.
  • a method is provided for selecting antibody against a membrane protein in vitro.
  • the method comprises: contacting a library of antibodies with an antigen that is a fusion protein between a peptide fragment of a target membrane protein and a heterologous chaperon protein that stabilizes the peptide fragment; and selecting the antibodies that bind to the antigen.
  • the chaperon protein may be any protein or a domain of a protein that is capable of stabilizing the fused peptide, for example, structurally stabilizing the conformation of the peptide under the condition of the immunization or screening process and/or preventing degradation of the peptide.
  • the chaperon protein may be a DNA binding domain (BD) or an activation domain (AD) of a transcription factor.
  • the chaperon protein may include Gal4 DNA binding domain, LexA binding domain, lambda cl DNA binding domain, cdc25 or Sos (guanine nucleotide exchange factor), T18 bacterial protein, T25 bacterial protein, the alpha and omega fragments of beta-lactamase, glutathion-S-transferase (GST) and thioredoxin.
  • the library of antibodies may be a library of antibodies mixed in solution, immobilized to a substrate in the form of an array, or displayed by mRNA, ribosome, phage, and cells such as yeast cells.
  • the antibodies in the library may be in the form of a single chain antibody, Fab antibody and fully assembled antibody.
  • a method for screening a library of single chain antibodies (scFv) against a target peptide in yeast comprising: expressing a library of scFv fusion proteins in yeast cells, each scFv fusion protein comprising either an activation domain or a DNA binding domain of a transcription activator and a scFv, the scFv comprising a VH of antibody whose sequence varies within the library, a V L of antibody whose sequence varies within the library independently of the VH, and a linker peptide which links the V H and V L ; expressing a target fusion protein in the yeast cells expressing the scFv fusion proteins, the target fusion protein comprising either the DNA binding domain or the activation domain of the transcription activator which is not comprised in the scFv fusion proteins, and a target peptide; and selecting those yeast cells in which a reporter gene is expressed, the expression of the reporter gene being activate
  • the diversity of the library scFv fusion proteins is preferably higher than 1x10 4 , more preferably higher than 1x10 6 , and most preferably higher than 1x10 7 .
  • the diversity of the library scFv fusion proteins is between 1x10 4 -1x10 11 , 1x10 6 -1x10 10 , 1x10 7 -1x10 10 , 1x10 7 - 1x10 9 , or 1x10 8 -1x10 10 .
  • a method for screening a library of antibodies against a target peptide in yeast comprising: expressing a library of antibody fusion proteins in yeast cells, each antibody fusion protein comprising either an activation domain or a DNA binding domain of a transcription activator which is fused with either VH or V L of the antibody, wherein the sequences of VH and V L of the antibody vary independently within the library, and the VH, V L and their fusions thereof are expressed as separate proteins and assemble in yeast to form the antibody fusion proteins; expressing a target fusion protein in the yeast cells expressing the antibody fusion proteins, the target fusion protein comprising either the DNA binding domain or the activation domain of the transcription activator which is not comprised in the antibody fusion proteins, and a target peptide; and selecting those yeast cells in which a reporter gene is expressed, the expression of the reporter gene being activated by a reconstituted transcriptional activator formed by binding of the antibody fusion protein to the target fusion protein.
  • the diversity of the library antibody fusion proteins is preferably higher than 1x10 4 , more preferably higher than 1x10 6 , and most preferably higher than 1x10 7 .
  • the diversity of the library antibody fusion proteins is between 1x10 4 -1x10 11 , 1x10 6 -1x10 10 , 1x10 7 -1x10 10 , 1x10 7 -1x10 9 , or 1x10 8 -1x10 10 .
  • the length of the target peptide is preferably 5-100 aa, more preferably 10-80 aa, and most preferably 20-60 aa.
  • the target peptide or peptide fragment may be a fragment of a protein that includes an antigenic determinant or epitope, preferably a fragment of a membrane protein, more preferably an extracellular domain of a membrane protein, and most preferably an extracellular loop of a transmembrane protein.
  • membrane protein examples include, but are not limited to, receptors for growth factors (e.g., vascular endothelial growth factor (VEGF), transforming growth factor (TGF), fibroblast growth factor (FF), platelet derived growth factor (PDGF), insulin-like growth factor), insulin receptor, MHC proteins (e.g., VEGF, vascular endothelial growth factor (VEGF), transforming growth factor (TGF), fibroblast growth factor (FF), platelet derived growth factor (PDGF), insulin-like growth factor), insulin receptor, MHC proteins (e.g.
  • growth factors e.g., vascular endothelial growth factor (VEGF), transforming growth factor (TGF), fibroblast growth factor (FF), platelet derived growth factor (PDGF), insulin-like growth factor
  • VEGF vascular endothelial growth factor
  • TGF transforming growth factor
  • FF fibroblast growth factor
  • PDGF platelet derived growth factor
  • insulin receptor e.g.
  • cytokine receptors e.g., interleukin (IL)-1 , IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11 , IL-12, IL-13, IL-14, IL-15 receptors
  • IL-10 interleukin-1 , IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11 , IL-12, IL-13, IL-14, IL-15 receptors
  • tyrosine-kinase- associated receptors such as Src, Yes, Fgr, Lck, Fit, Lyn, Hck, and Blk
  • G- protein coupled receptors such as receptors for the hormone relaxin (LGR7 and LGR8) and chemokine receptor (e.g., CCR1 , CCR2, CCR3, CCR4, CCR5,
  • the target peptide or peptide fragment may also be derived from a viral surface or core protein.
  • viral proteins include, but are not limited to, glycoproteins (or surface antigens, e.g., GP120 and GP41) and capsid proteins (or structural proteins, e.g., P24 protein); surface antigens or core proteins of hepatitis A, B, C, D or E virus (e.g. small hepatitis B surface antigen (SHBsAg) of hepatitis B virus and the core proteins of hepatitis C virus,
  • SHBsAg small hepatitis B surface antigen
  • NS3, NS4 and NS5 antigens glycoprotein (G-protein) or the fusion protein (F- protein) of respiratory syncytial virus (RSV); surface and core proteins of herpes simplex virus HSV-1 and HSV-2 (e.g., glycoprotein D from HSV-2).
  • the target peptide comprises an extracellular domain of human CCR5 selected from the group consisting of N-terminal domain, loop 2, loop 4, and loop 6 of human CCR5.
  • the extracellular domain of human CCR5 comprises a sequence selected from the group consisting of SEQ ID Nos: 2, 3, 8, and 9.
  • the target peptide comprises an extracellular domain of human CXCR4 selected from the group consisting of N-terminal domain, loop 2, loop 4, and loop 6 of human CXCR4.
  • the extracellular domain of human CXCR4 comprises SEQ ID NO: 58.
  • the activation domain or the DNA binding domain of the transcription activator may optionally be fused to C- terminus of the scFv, or to the N-terminus of the scFv.
  • the activation domain or the DNA binding domain of the transcription activator may optionally be fused to C- terminus of the target peptide, or to the N-terminus of the target peptide.
  • the step of expressing the library of scFv fusion proteins in yeast cells may include transforming a library of scFv expression vectors into the yeast cells which contain the reporter gene.
  • the step of expressing the target fusion proteins includes transforming a target expression vector into the yeast cells simultaneously or sequentially with the library of scFv expression vectors.
  • the steps of expressing the library of scFv fusion proteins and expressing the target fusion protein may optionally include causing mating between first and second populations of haploid yeast cells of opposite mating types.
  • the first population of haploid yeast cells comprises a library of scFv expression vectors for the library of scFv fusion proteins.
  • the second population of haploid yeast cells comprises a target expression vector. Either the first or second population of haploid yeast cells comprises the reporter gene.
  • the haploid yeast cells of opposite mating types may preferably be ⁇ and a type strains of yeast.
  • the mating between the first and second populations of haploid yeast cells of ⁇ and a type strains may be conducted in a rich nutritional culture medium.
  • the above-described target peptide fragment derived from a membrane protein may be screened against an antibody library in other organisms or in vitro.
  • the target peptide may be expressed as a fusion protein with another protein and screened against an antibody library co-expressed in mammalian cells.
  • the target peptide may also be immobilized to a substrate as a single peptide or a fusion protein and selected against a library of antibodies displayed by mRNA, ribosome, phage or cells such as yeast cells.
  • the target peptide may be introduced to a xenomouse, a HuMab mouse, or a transchromosomal mouse that contains a library of human antibody, and selected for monoclonal human antibodies with specific binding affinity to target peptide and/or the target membrane protein.
  • compositions that comprise at least one of the heavy chain and light chain variable region of an antibody are provided which recognize epitopes on the extracellular domains of human CCR5.
  • the composition comprises an antibody that binds to loop 6 of human CCR5.
  • the antibody is capable of inhibiting HIV- 1 infection of human cells.
  • the antibody may be a polyclonal or a monoclonal antibody, including but not limited to fully assembled antibody, single chain antibody, Fab fragment, and chimeric antibody.
  • CDR2 of the heavy chain variable region of the antibody comprises amino acid sequence GSTXiYNPSL [SEQ ID NO: 32], wherein Xi is asparagine (N) or threonine (T).
  • CDR2 of the light chain variable region of the antibody comprises amino acid sequence DAX 2 X 3 L [SEQ ID NO: 33], wherein X 2 is threonine (T) or serine (S), and X 3 is threonine (T) or aspartic acid (D).
  • CDR2 of the heavy chain variable region of the antibody comprises amino acid sequence GSTXiYNPSL [SEQ ID NO: 32]; and CDR2 of the light chain variable region of the antibody comprises amino acid sequence
  • DAX 2 X 3 L [SEQ ID NO: 33], wherein X ⁇ is asparagine (N) or threonine (T), X 2 is threonine (T) or serine (S), and X 3 is threonine (T) or aspartic acid (D).
  • CDR3 of the heavy chain variable region of the monoclonal antibody comprises 5, 6, 7, 8, 9 or more consecutive amino acids of a sequence elected from the group consisting of
  • CDR3 of the light chain variable region of the monoclonal antibody comprises 5, 6, 7, 8, 9 or more consecutive amino acids of a sequence elected from the group consisting of AAWDESLNGVV [SEQ ID NO: 46],
  • CDR3 of the heavy chain variable region of the monoclonal antibody comprises an amino acid sequence selected from the group consisting of SEQ ID Nos: 43-45; and CDR3 of the light chain variable region of the monoclonal antibody comprises an amino acid sequence selected from the group consisting of SEQ ID Nos: 46-48.
  • CDR3 of the heavy chain variable region of the antibody comprises an amino acid sequence selected from the group consisting of SEQ ID Nos: 43-45; and CDR3 of the light chain variable region of the antibody comprises an amino acid sequence selected from the group consisting of SEQ ID Nos: 46-48.
  • the heavy chain variable region of the antibody comprises an amino acid sequence selected from SEQ ID Nos: 36, 38, and 40.
  • the light chain variable region of the antibody comprises an amino acid sequence selected from SEQ ID Nos: 37, 39, and 41.
  • compositions that comprise at least one of the heavy chain and light chain variable region of an antibody are provided which recognize epitopes on the extracellular domains of human CXCR4.
  • the composition comprises an antibody that binds to loop 6 of human CXCR4.
  • the antibody is capable of inhibiting
  • the antibody is capable of inhibiting chemotaxis of cells, optionally human cancer cells, optionally human breast cancer cells.
  • the antibody may be a polyclonal or a monoclonal antibody, including but not limited to fully assembled antibody, single chain antibody, Fab fragment, and chimeric antibody.
  • the antibody is a single chain antibody encoded by DNA SEQ ID NO: 59 or 62.
  • the heavy chain variable region of the antibody comprises an amino acid sequence with SEQ ID NO: 60 or 63.
  • the light chain variable region of the antibody comprises an amino acid sequence with SEQ ID NO: 61 or 64.
  • the antibody of the present invention may be produced by expression in bacteria, yeast, plant, and animal cells in any form including but not limited to single chain, Fab, full length IgA, secretion form slgA, or IgG.
  • the antibody of present invention may be used for the prevention or treatment of HIV infection.
  • the antibodies against human CCR5 may be administered to an individual with high risk of HIV infection or already infected with HIV to block the entry of HIV-1 into the cells.
  • the antibody of present invention may also be conjugated with a molecule such as an antiviral drug and a radio-isotope to specifically target cells expressing human CCR5 and/or CXCR4.
  • the antibody of the present invention may be used in a therapy for the treatment of various diseases such as cancer, autoimmune diseases, and viral infection.
  • the antibody may also be used in a combination therapy in conjunction with other therapeutic agents such as anti-viral agents (e.g., nucleoside or non-nucleoside HIV reverse transcriptase inhibitors, HIV protease inhibitors, and HIV integrase inhibitors), and anti-neoplastic agents.
  • nucleoside HIV reverse transcriptase inhibitor examples include, but are not limited to zidovudine (AZT), didanosine (ddl), zalcitabine (ddC), lamivudine (3TC), stavudine (d4T), abacavir (1592U89), and adefovir dipivoxil (bis(POM)-PMEA).
  • non-nucleoside HIV reverse transcriptase inhibitor include, but are not limited to nevirapine (BI-RG-587), delavirdine
  • HIV protease inhibitors include, but are not limited to indinavir (MK-639), ritonavir (ABT-538), saqinavir (Ro-31-8959), nelfinavir (AG-1343), and amprenavir (141W94).
  • anti-neoplastic agents include, but are not limited to, alkylating agents (e.g., cyclophosphamide and cisplatin), antibiotic agents (e.g., doxorubicin, mitomycin C, and bleomycin), antimetabolic agents (e.g., fluorouracil (5-FU) and methotrexate), hormonal agents (e.g., tamoxifen), plant- derived agents (paclitaxel, vincristine and camptothecin), and biologic agents (e.g., monoclonal antibodies such as HERCEPTIN® (Trastruzumab) and RITUXAN® (Rituximab), and cytokines).
  • alkylating agents e.g., cyclophosphamide and cisplatin
  • antibiotic agents e.g., doxorubicin, mitomycin C, and bleomycin
  • antimetabolic agents e.g., fluorouracil (5-FU)
  • the antibody of the present invention may be administered to a mammal, preferably a human, via a variety of routes, including but not limited to, orally, parenterally, intraperitoneally, intravenously, intraarterially, topically, transdermally, sublingually, intramuscularly, rectally, transbuccally, intranasally, liposomally, via inhalation, vaginally, intraoccularly, via local delivery (for example by catheter or stent), subcutaneously, intraadiposally, intraarticularly, or intrathecally.
  • the antibody may also be delivered to the host locally (e.g., via stents or cathetors) and/or in a timed-release manner.
  • the antibody of the present invention may be used for diagnosis of diseases associated with membrane proteins interactions such as CXCR4 and CCR5, the co-receptors of HIV. Moreover, the antibody may be used in assays for screening therapeutic agents against these diseases.
  • Figure 1A shows the amino acid sequence of human CCR5.
  • Figure 1B shows the amino acid sequences of peptide fragments derived from human CCR5 that are used as target peptides for eliciting antibody according to the present invention.
  • Figure 1C shows and a model of the secondary structure of human CCR5.
  • Figure 2A illustrates an embodiment of the method of present invention for screening of scFv against a target peptide derived from a membrane protein via transformation of yeast cells.
  • Figure 2B illustrates another embodiment of the method of present invention for screening of scFv against a target peptide derived from a membrane protein via mating of two yeast strains.
  • Figure 3 illustrates a method of constructing a human scFv antibody library via homologous recombination in yeast.
  • Figure 4 illustrates a method of affinity maturation of an antibody lead.
  • Figure 5 shows DNA and amino acid sequences of four distinct scFv antibodies against human CCR5 fragments.
  • Figure 6 shows DNA and amino acid sequences of variants of the four scFv antibodies against human CCR5 fragments.
  • Figure 7 shows a homology alignment of amino acid sequences of three scFv antibodies against human CCR5 Loop ⁇ .
  • Figure 8 shows amino acid sequences of V H and V of the four scFv antibodies against human CCR5 fragments.
  • Figures 9A-C show HIV-1 reverse transcriptase (RT) activity in a culture of human monocytes infected by HIV-1 in the present or absent of antibody on day 4, 8, and 12 post infection, respectively.
  • RT HIV-1 reverse transcriptase
  • Figures 10A-C show viability of a culture of human monocytes infected by HIV-1 in the present or absent of antibody on day 4, 8, and 12 post infection, respectively.
  • Figures 11A-C show HIV-1 reverse transcriptase (RT) activity in a culture of human monocytes infected by HIV-1 in the present or absent of antibody at lower concentrations than those in Figures 9A-C on day 4, 8, and 12 post infection, respectively.
  • RT reverse transcriptase
  • Figure 12 shows a Western blot of CCR5 expressed by human macrophage probed by scFv against human CCR5 Loop 6.
  • Figure 13 is a graph showing that two scFv against human CCR5 Loop 6 are both capable of blocking the binding of MIP-1 ⁇ to CCR5 on human monocyte-derived macrophages.
  • Figure 14 is a graph showing that non-labeled CCR5 ligands, MIP-1 ⁇ and RANTES, can compete with radio-labeled MIP-1 ⁇ in binding with CCR5 on human monocyte-derived macrophages.
  • Figure 15 shows DNA sequence, amino acid sequences of VH and VL of single chain antibodies Ab124 and Ab125.
  • Figure 16 is a graph showing that single chain antibodies Ab124 and Ab125 can inhibit SDF-1 induced chemotaxis in human breast cancer line MDA- MB-231.
  • the present invention provides innovative methods for efficient, high throughput screening of antibody library against a wide variety of target proteins, especially membrane proteins.
  • the methods can be used to systematically and efficiently screen human antibody against epitopes on a target protein and select for antibodies with high affinity and efficacy in regulating the biological functions of the target protein.
  • fully human antibodies can be selected by using these methods to target therapeutically significant membrane proteins, such as cell surface co-receptors for HIV envelope protein (e.g., CXCR4 and CCR5).
  • Membrane proteins are generally considered to be evasive targets for screening agents for therapeutic intervention and rational drug design because of difficulties associated with isolation and purification, as well as the structural uncertainty of the isolated protein adopted in vitro.
  • skilled artisans resorted to using cells expressing the whole protein of the membrane protein such as CCR5 as an immunogen to elicit monoclonal antibody against it.
  • peptide fragments of a membrane protein can be excellent targets against which high affinity antibody can be selected in a yeast two-hybrid system.
  • the peptide fragment is expressed as a target fusion protein with the DNA-binding domain (BD) (or the activation domain (AD)) of a transcription activator in yeast cells.
  • BD DNA-binding domain
  • AD activation domain
  • a library of fully human single-chain antibody is expressed as tester fusion proteins with the AD (or the BD) of the transcription activator in the same yeast cells. Binding of the antibody to the peptide target triggers expression of a reporter gene in the yeast cell, which facilitates identification and isolation of the clones containing the monoclonal human antibody.
  • a peptide fragment derived from a membrane protein when fused with a heterologous protein that acts like a chaperon to stabilize the conformation adopted by the peptide in isolation from the membrane protein, can serve as an immunogen to elicit antibody in an animal or as a target ligand in screening assays in vitro.
  • the fusion protein formed by the peptide and the chaperon protein may present the peptide in a conformation similar to that adopted by the peptide in its native context, i.e., in the membrane protein located on the cell.
  • extracellular loops adopted by stretches of peptide sequences in the membrane protein are attractive targets because these loops can serve as accessible epitopes for extracellular binding with antibodies to block downstream signal transduction mediated by the membrane protein. This feature is desirable for therapeutic and diagnostic applications targeting cells expressing the membrane protein.
  • a method for eliciting antibodies against a membrane protein in a non-human animal.
  • the method comprises: immunizing a non-human animal with an antigen that is a fusion protein between a peptide fragment of a target membrane protein and a heterologous chaperon protein that stabilizes the peptide fragment.
  • the step of immunizing the animal may include injecting the antigen directly into the animal.
  • the antigen may be injected into a mouse to elicit polyclonal antibodies, or monoclonal antibodies by using a conventional hybridoma technology, examples of which are described in detail in Section 2 below.
  • the animal may be a natural animal, a transgenic animal that has been genetically modified to produce human antibodies, such as XENOMOUSE® and HuMab Mouse, or a transchromosome (TC) mouse (Tomizuka et al. (2000) Proc Natl Acad Sci USA. 97:722-727. This document, and all documents cited to herein, are incorporated by reference as if fully reproduced below).
  • the fusion protein formed by the peptide and the chaperon protein may be administered into a XENOMOUSE® by following protocols described in U.S. Patent Nos: 6,075,181 and 6,114,598 which are incorporated herein by reference. Briefly, two to six xenomice aged 6-30 weeks are age- matched and immunized intraperitoneally with 10-100 ⁇ g of the fusion protein in complete Freund's adjuvant for primary immunization and in incomplete Freund's adjuvant for subsequent injections. The mice received 6 injections 2-3 weeks apart. Serum titers are determined after the second dose and following each dose thereafter. Bleeds are performed 6-7 days after injections from the retrobulbar plexus.
  • the blood is allowed to clot at room temperature for about 2 hours and then incubated at 4°C for at least 2 hours before separating and collecting the sera.
  • the sera of the immunized xenomice (or the supernatants from immortalized B cells) are titrated for antigen specific human antibodies using a standard ELISA assay.
  • the antigen used for immunization i.e., the fusion protein
  • bound antibody having human characteristics are detected by adding the appropriate antispecies Ig (typically antihuman K or antihuman ⁇ ) conjugated to horseradish peroxidase (HRP) for one hour.
  • the bound antibodies may be tested for murine characteristics using antimurine antibodies, typically antimurine ⁇ .
  • the chromogenic reagent o-phenylene diamine (OPD) substrate and hydrogen peroxide are added and the plates are read 30 minutes later at 492 nm using a microplate reader.
  • the hybridoma secreting the target antigen- binding antibodies is used to obtain the cDNA encoding fully human variable regions.
  • the step of immunizing the animal may include transfecting the animal with an expression vector encoding the antigen.
  • DNA sequence encoding the antigen can be inserted into a mammalian expression vector or a viral vector (e.g., retroviral, adnoviral, and adeno-associated viral vectors) and the resulting expression vector can be injected into the animal where the expression of the antigen by the vector elicits immune responses to the antigen.
  • Antibodies can then be isolated from the serum of the animal and used to target the membrane protein for therapeutic or diagnostic purposes.
  • a method for selecting antibody against a membrane protein in vitro comprises: contacting a library of antibodies with an antigen that is a fusion protein between a peptide fragment of a target membrane protein and a heterologous chaperon protein that stabilizes the peptide fragment; and selecting the antibodies that bind to the antigen.
  • the library of antibodies may be a library of antibodies mixed in solution, immobilized to a substrate in the form of an array, or displayed by mRNA, ribosome, phage, and cells such as yeast cells.
  • the antibodies in the library may be in the form of a single chain antibody, Fab antibody and fully assembled antibody.
  • the chaperon protein may be any protein or a domain of a protein that is heterologous to the membrane protein and capable of stabilizing the fused peptide, for example, structurally stabilizing the conformation of the peptide under the condition of the immunization or screening process and/or preventing degradation of the peptide.
  • the chaperon protein may be a DNA binding domain (BD) or an activation domain (AD) of a transcription factor.
  • the chaperon protein may include Gal4 DNA binding domain, LexA binding domain, lambda cl DNA binding domain, cdc25 or Sos (guanine nucleotide exchange factor), T18 bacterial protein, T25 bacterial protein, the alpha and omega fragments of beta-lactamase, glutathion-S-transferase (GST) and thioredoxin.
  • the present invention provides a method for selecting monoclonal single chain antibody (scFv) against a peptide target.
  • a single chain antibody generally includes a heavy chain variable region (VH) of antibody covalently linked to a light chain variable region (V L ) of antibody via a peptide linker.
  • the method comprising: expressing a library of scFv fusion proteins in yeast cells, each scFv fusion protein comprising either an activation domain or a DNA binding domain of a transcription activator and a scFv, the scFv comprising a V H of antibody whose sequence varies within the library, a V L of antibody whose sequence varies within the library independently of the V H , and a linker peptide which links the VH and V L ; expressing a target fusion protein in the yeast cells expressing the scFv fusion proteins, the target fusion protein comprising either the DNA binding domain or the activation domain of the transcription activator which is not comprised in the scFv fusion proteins, and a target peptide having a length of 5- 100 amino acid residues (aa); and selecting those yeast cells in which a reporter gene is expressed, the expression of the reporter gene being activated by a reconstituted transcriptional activator formed by binding of the scFv fusion
  • the diversity of the library scFv fusion proteins is preferably higher than 1x10 4 , more preferably higher than 1x10 6 , and most preferably higher than 1x10 7 .
  • the length of the target peptide is preferably 10-80 aa, more preferably 20-60 aa, and most preferably 30-50 aa.
  • the target peptide is preferably a fragment of a membrane protein, more preferably an extracellular domain of a membrane protein, and most preferably an extracellular loop of a transmembrane protein.
  • antibodies with high affinity and specificity can be selected against the target peptide expressed as a fusion protein in vivo and in vitro.
  • inventive method for screening in yeast may provide a more efficient and economical way to screen for fully human antibodies against virtually any target peptide in a much shorter period of time. More importantly, the screening of the antibody libraries can be readily adopted for high throughput screening in vivo.
  • the method of the present invention has been used for screening fully human antibody library against HIV coreceptors such as CCR5 and CXCR4 in yeast.
  • HIV coreceptors such as CCR5 and CXCR4
  • single chain antibodies against fragments of CCR5 have been selected and demonstrated to bind to human CCR5 with high affinity and inhibit HIV-1 infection at sub-nanomolar concentrations.
  • the overall process of screening in yeast is very efficient and high throughput.
  • each domain (or fragment) of the protein can be can systematically screened against the same library of human antibody with high diversity (>1x10 7 ). Since the peptide comprising the domain is expressed intracellularly and screened for binding with the library of antibody intracellulary, the peptide needs not be isolated or synthesized in vitro, thus greatly simplifying the process and reducing labor and cost.
  • murine monoclonal antibodies of desired antigen specificity are modified or "humanized” in vitro in an attempt to reshape the murine antibody to resemble more closely its human counterpart while retaining the original antigen-binding specificity.
  • This humanization demands extensive, systematic genetic engineering of the murine antibody, which could take months, if not years. Additionally, extensive modification of the backbone of the murine monoclonal antibody may result in reduced specificity and affinity.
  • any peptide fragment derived from the target protein can be expressed as a fusion protein with a chaperon protein, such as a DNA-binding domain (or an activation domain) of a transcription activator and selected against the library of antibody in vivo or in ' vitro (e.g., in a yeast-2-hybrid system).
  • a chaperon protein such as a DNA-binding domain (or an activation domain) of a transcription activator
  • multiple peptide targets may be arrayed in multiple-well plates and screened against the library of antibodies in a high throughput and automated manner.
  • the target peptide is a fragment of a membrane protein.
  • the target peptide is expressed in yeast as a target fusion protein with either a DNA binding domain or an activation domain of a transcription activator which is not comprised in the scFv fusion proteins.
  • the epitope on the target peptide is presented by the target fusion protein in yeast and recognized by some member(s) in the library of scFv fusion proteins. Such interactions trigger expression of a reporter gene within the same cell, allowing identification of the yeast clones expressing the binding scFv fusion protein.
  • Plasma membrane encloses the cell by forming a selective permeability barrier, defines its boundaries, and maintains the essential differences between the cytosol and the extracellular environmen.
  • the plasma membrane consists lipids, proteins, and some carbohydrates. Lipids form a bilayer in which the membrane proteins are embedded to varying degrees. Different membrane proteins are associated with the membranes in different ways. Many membrane proteins extend through the lipid bilayer, with part of their mass on either side. These transmembrane proteins are amphipathic, having regions that are hydrophobic and regions that are hydrophilic. Their hydrophilic regions are exposed to water on one or the other side of the membrane.
  • membrane proteins are located entirely in the cytosol and are associated with the bilayer only by means of one or more covalently attached fatty acid chains or other types of lipid chains called prenyl groups. Yet other membrane proteins are entirely exposed at the external cell surface, being attached to the bilayer only the covalent linkage (e.g., via a specific oligosaccharide) to phosphatidylinositol in the outer lipid monolayer of the plasma membrane.
  • the membrane protein is a transmembrane protein.
  • a transmembrane protein has its cytoplasmic and extracellular domains which are separated by the membrane-spanning segments of the polypeptide chain.
  • the membrane-spanning segments contact the hydrophobic environment of the lipid bilayer and are composed largely of amino acid residues with non-polar side chains.
  • the great majority of transmembrane proteins are glycosylated.
  • the oligosaccharide chains are usually present in the excellular domain.
  • the reducing environment of the cytosol prevents the formation of intrachain (and interchain) disulfide (S-S) bonds between cysteine residues on the cytosolic side membranes.
  • transmembrane proteins are notoriously difficult to crystallize for X-ray structural studies.
  • the folded three-dimensional structures are quite uncertain for the isolated forms of these proteins.
  • these features present a problem in the attempt to use the whole transmembrane protein as a target for isolating molecules that would bind to it in vitro.
  • a peptide fragment derived from one of the extracellular domains of the transmembrane protein could serve as the target peptide.
  • Antibody selected by using the screening methods of present invention binds to the exacelluar cellular domain, thereby effectively blocking interactions of the transmembrane protein with its excellular ligand.
  • the membrane protein include, but are not limited to, receptors for growth factors (e.g., vascular endothelial growth factor (VEGF), transforming growth factor (TGF), fibroblast growth factor (FF), platelet derived growth factor (PDGF), insulin-like growth factor), insulin receptor, MHC proteins (e.g.
  • cytokine receptors e.g., interleukin (IL)-1 , IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8,
  • IL-9, IL-10, 1L-11 , IL-12, IL-13, IL-14, IL-15 receptors tyrosine-kinase- associated receptors
  • tyrosine-kinase- associated receptors such as Src, Yes, Fgr, Lck, Fit, Lyn, Hck, and Blk
  • G- protein coupled receptors such as receptors for the hormone relaxin (LGR7 and LGR8) and chemokine receptors (e.g., CCR1 , CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10, CCR11 , CXCR1 , CXCR2, CXCR3,
  • G protein-coupled receptors are a superfamily of transmembrane proteins that play important roles in the signal transduction process of a cell. GPCR mediates the cellular responses to an enormous diversity of signaling molecules, including hormones, neurotransmitters, and local mediators. The signal molecules vary in their structure and function, including proteins, small peptides, as well as amino acid and fatty acid derivatives. See reviews by Watson S., and Arkinstall S.: "The G-Protein Linked Receptor Facts Book”. 1994, Academic Press, Harcourt Brace & Company, Publishers. London, San Diego, New York; Proudfoot A.E.I.: "Chemokine Receptors: Multifaceted
  • G-protein guanine nucleotide binding protein
  • LGR7 and LGR8 are capable of mediating the action of relaxin through an adenosine 3',5'-monophosphate (cAMP)-dependent pathway distinct from that of the structurally related insulin and insulin-like growth factor.
  • cAMP adenosine 3',5'-monophosphate
  • GPCRs share a structural similarity in that the polypeptide chain threads back and forth across the lipid bilayer several times, e.g., seven times to form 7 transmembrane domains which are connected by 3 extracellular loops and 3 intracellular loops.
  • CCR5 and CXCR4 are chemokine receptors are members of the GPCR superfamily.
  • CCR5 is a receptor for several CC chemokines such as MIP-1 ⁇ (also named GOS19, LD78, pAT464 gene product, TY5 (murine) and
  • SIS ⁇ (murine)
  • MIP-1 ⁇ also named Act-2, G-26, pAT744 gene product, H-400 (murine) and hSIS ⁇ (murine)
  • RANTES regulated on activation, normal T cell expressed and secreted, or CCL5
  • CXCR4 also named LESTR or fusin before
  • the lymphocyte chemoattractant stromal cell derived factor-1 (or SDF-1) or CXCL12 is a ligand for CXCR4 (Bleul CC, et al. (1996) Nature. 382:829-833).
  • CXCR4 acts as a coreceptor of HIV-1 (Feng Y, (1996) Science 272:872-877). Its expression is also correlated with cancer, including prostate cancer (Taichman RS, et al (2002) Cancer Res. 62:1832-1837) and breast caner metastasis (Muller A, et al (2001) Nature. 410:50-56; and Moore MA. (2001) Bioessays. 23:674-676).
  • the inventive methodology disclosed herein can be used to generate antibodies against these chemokine receptors.
  • the resultant antibodies can then be used for the prevention and/or treatment of
  • human monoclonal single chain antibodies against CCR5 and CXCR4 were generated using the inventive methods and used to inhibit HIV infection of peripheral blood mononuclear cells and chemotaxis in breast cancer cells, respectively.
  • Figure 1A shows the amino acid sequence of human CCR5 with 7 transmembrane domains that are connected by loops 2, 4, and 6 which are extracellular loops and by loops 1 , 3, 5 which are intracellular loops.
  • Figure 1B shows a model of the secondary structure of human CCR5. Blanpain et al. (1999) J. Biol. Chem. 274:34719-34727. In particular, peptides derived from excellular loops of the membrane protein could serve an ideal target for screening against the library of antibody.
  • examples of a chemokine receptor or a chemokine receptor-like orphan receptor also include, but are not limited to, CCR1 , CCR2b, CCR3, CCR4, CCR8, CXCR1 , CXCR2, CXCR3, CX 3 CR1 ,
  • the target peptide may be derived from any protein.
  • the target peptide may be derived from a disease-associated antigen, such as tumor surface antigen such as B-cell idiotypes, CD20 on malignant B cells, CD33 on leukemic blasts, and HER2/neu on breast cancer.
  • Antibody selected against these antigens can be used in a wide variety of therapeutic and diagnostic applications, such as treatment of cancer by direct administration of the antibody itself or the antibody conjugated with a radioisotope or cytotoxic drug, and in a combination therapy involving coadministration of the antibody with a chemotherapeutic agent, or in conjunction with radiation therapy.
  • the target peptide may be derived from a growth factor receptor.
  • the growth factor include, but are not limited to, epidermal growth factors (EGFs), transferrin, insulin-like growth factor, transforming growth factors (TGFs), interleukin-1, and interleukin-2.
  • EGFs epidermal growth factors
  • TGFs transforming growth factors
  • interleukin-1 interleukin-1
  • interleukin-2 interleukin-2
  • TGF- ⁇ have been found to mediate an autocrine stimulation pathway in cancer cells.
  • Several murine monoclonal antibody have been demonstrated to be able to bind EGF receptors, block the binding of ligand to EGF receptors, and inhibit proliferation of a variety of human cancer cell lines in culture and in xenograft medels.
  • the target peptide may also be derived from a cell surface protein or receptor associated with coronary artery disease such as platelet glycoprotein lib/Ilia receptor, autoimmune diseases such as CD4, CAMPATH-1 and lipid A region of the gram-negative bacterial lipopolysaccharide.
  • a cell surface protein or receptor associated with coronary artery disease such as platelet glycoprotein lib/Ilia receptor, autoimmune diseases such as CD4, CAMPATH-1 and lipid A region of the gram-negative bacterial lipopolysaccharide.
  • Humanized antibodies against CD4 has been tested in clinical trials in the treatment of patients with mycosis fungoides, generalized postular psoriasis, severe psorisis, and rheumatoid arthritis.
  • Antibodies against lipid A region of the gram-negative bacterial lipopolysaccharide have been tested clinically in the treatment of septic shock.
  • Antibodies against CAMPATH-1 has also been tested clinically in the treatment of against refractory rheumatoid arthritis.
  • fully human antibodies selected against these growth factors by using the method of the present invention can be used to treat a variety of autoimmune diseases (Vaswani et al. (1998) "Humanized antibodies as potential therapeutic drugs” Annals of Allergy, Asthma and Immunology 81:105-115); inflammation (Present et al. (1999) "Infliximab for the treatment of fistulas in patients with Crohn's disease” N Engl J Med. 340:1398-1405); and immuno-rejection in transplantation (Nashan et al. (1999) "Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group", Transplantation 67: 110-115.
  • the target peptide may also be derived from proteins associated with human allergic diseases, such as those inflammatory mediator protein, e.g. lnterleukin-1 (IL-1), tumor necrosis factor (TNF), leukotriene receptor and 5- lipoxygenase, and adhesion molecules such as V-CAM/VLA-4.
  • IgE may also serve as the target antigen because IgE plays pivotal role in type I immediate hypersensitive allergic reactions such as asthma. Studies have shown that the level of total serum IgE tends to correlate with severity of diseases, especially in asthma. Burrows et al. (1989) "Association of asthma with serum IgE levels and skin-test reactivity to allergens" New Engl. L. Med. 320:271-277.
  • fully human antibodies selected against IgE by using the method of the present invention may be used to reduce the level of IgE or block the binding of IgE to mast cells and basophils in the treatment of allergic diseases without having substantial impact on normal immune functions.
  • the target peptide may also be derived from a viral surface or core protein which may serve as an antigen to trigger immune response of the host.
  • viral proteins include, but are not limited to, glycoproteins (or surface antigens, e.g., GP120 and GP41) and capsid proteins (or structural proteins, e.g., P24 protein); surface antigens or core proteins of hepatitis A, B, C, D or E virus (e.g.
  • SHBsAg small hepatitis B surface antigen of hepatitis B virus and the core proteins of hepatitis C virus, NS3, NS4 and NS5 antigens
  • G-protein glycoprotein
  • F-protein fusion protein
  • RSV respiratory syncytial virus
  • humanized monoclonal antibody has been developed for the prevention of respiratory syncytial virus (RSV) infection.
  • Storch 1998 "Humanized monoclonal antibody for prevention of respiratory syncytial virus infection” Pediatrics. 102:648-651.
  • the target peptide may also be derived from a mutated tumor suppressor gene that have lost its tumor-suppressing function and may render the cells more susceptible to cancer.
  • Tumor suppressor genes are genes that function to inhibit the cell growth and division cycles, thus preventing the development of neoplasia.
  • Mutions in tumor suppressor genes cause the cell to ignore one or more of the components of the network of inhibitory signals, overcoming the cell cycle check points and resulting in a higher rate of controlled cell growth — cancer.
  • the tumor suppressor genes include, but are not limited to, DPC-4, NF-1, NF-2, RB, p53, WT1, BRCA1 and BRCA2.
  • DPC-4 is involved in pancreatic cancer and participates in a cytoplasmic pathway that inhibits cell division.
  • NF-1 codes for a protein that inhibits Ras, a cytoplasmic inhibitory protein.
  • NF-1 is involved in neurofibroma and pheochromocytomas of the nervous system and myeloid leukemia.
  • NF-2 encodes a nuclear protein that is involved in meningioma, schwanoma, and ependymoma of the nervous system.
  • RB codes for the pRB protein, a nuclear protein that is a major inhibitor of cell cycle. RB is involved in retinoblastoma as well as bone, bladder, small cell lung and breast cancer.
  • P53 codes for p53 protein that regulates cell division and can induce apoptosis. Mutation and/or inaction of p53 is found in a wide ranges of cancers.
  • WT1 is involved in Wilms tumor of the kidneys.
  • BRCA1 is involved in breast and ovarian cancer, and
  • BRCA2 is involved in breast cancer.
  • fully human antibodies selected against a mutated tumor suppressor gene product by using the method of the present invention can be used to block the interactions of the gene product with other proteins or biochemicals in the pathways of tumor onset and development.
  • CCR5 Loop 6 certain fragments derived from loop 6 of CCR5 present excellent epitopes for recognition by antibodies.
  • the epitope(s) on CCR5 Loop 6 can be used to elicit antibody by using the method of present invention or other methods for generating antibody known in the art.
  • CCR5 Loop 6 includes amino acid residue aa 261-277: QEFFGLNNCSSSNRLDQ [SEQ ID NO:2] (shown in Figure 1A).
  • a peptide fragment containing most of the Loop 6 region and a portion of transmembrane domain 7, EFFGLNNCS SSNRLDQAMQ VTETLGMTHC [SEQ ID NO:3] could elicit monoclonal antibodies that bind to CCR5 with high affinity and inhibit HIV-1 infection at sub- nanomolar concentrations.
  • a peptide comprising a substantial portion of Loop 6 may serve as an epitope for elicit antibodies by using the method of the present invention or conventional methods such as hybridoma techniques and bacteriophage display panning.
  • the loop 6 peptide may be fused with a chaperon protein such as Gal4 DNA binding domain to form a fusion protein.
  • a fusion protein can be used as an immunogen for eliciting antibodies in animals or as a ligand for screening an antibody library in vitro.
  • the antibodies against CCR5 Loop 6 include but are not limited to polyclonal, monoclonal, Fab fragments, single chain antibodies, chimeric antibodies (e.g., humanized antibodies), etc.
  • various host animals may be immunized by injection with an immunogen containing a peptide derived from CCR5 Loop 6.
  • Such host animals may include but are not limited to rabbits, mice, and rats, to name but a few.
  • adjuvants may be used to increase the immunological response, depending on the host species, including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and Corynebacterium parvum.
  • BCG Bacille Calmette-Guerin
  • Corynebacterium parvum bacille Calmette-Guerin
  • Polyclonal antibodies are heterogeneous populations of antibody molecules derived from the sera of animals immunized with an antigen, such as a peptide derived from CCR5 Loop 6 or its fusion with a chaperon protein, or an antigenic functional derivative thereof.
  • an antigen such as a peptide derived from CCR5 Loop 6 or its fusion with a chaperon protein, or an antigenic functional derivative thereof.
  • host animals such as those described above, may be immunized by injection with a peptide comprising a portion of CCR5 Loop 6 supplemented with adjuvants as also described above.
  • a protein that is immunogenic in the species to be immunized e.g., keyhole limpet hemocyanin (KLH), serum albumin, bovine thyroglobulin, or soybean trypsin inhibitor
  • KLH keyhole limpet hemocyanin
  • serum albumin serum albumin
  • bovine thyroglobulin bovine thyroglobulin
  • soybean trypsin inhibitor e.g., a bifunctional or derivatizing agent, for example, maleimidobenzoyl sulfosuccinimide ester (conjugation through cysteine residues), N-hydroxysuccinimide (through lysine residues), glutaraldehyde, succinic anhydrid or SOCI 2 .
  • a bifunctional or derivatizing agent for example, maleimidobenzoyl sulfosuccinimide ester (conjugation through cysteine residues), N-hydroxysuccinimide (through ly
  • animals are immunized against CCR5 Loop 6 peptide or its immunogenic conjugates by combining, e.g., 100 ⁇ g or 5 ⁇ g of the protein or conjugate (for rabbits or mice, respectively) with 3 volumes of Freund's complete adjuvant and injecting the solution intradermally at multiple sites.
  • the animals are boosted with 1/5 or 1/10 the original amount of peptide or conjugate in Freund's complete adjuvant by subcutaneous injection at multiple sites.
  • the animals are bled and the serum is assayed for antibody titer. Animals are boosted until the titer plateaus.
  • the animal is boosted with conjugate of the same antigen, but conjugated to a different protein and/or through a different cross-linking reagent.
  • Conjugates can also be made in recombinant cell culture as protein fusions.
  • aggregating agents such as alum are suitably used to enhance the immune response.
  • Monoclonal antibodies which are homogeneous populations of antibodies to a particular antigen, may be obtained by any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to the hybridoma technique of Kohler and Milstein (1975) Nature 256:495-497; and U.S. Pat. No. 4,376,110, the human B-cell hybridoma technique (Kosbor et al. (1983) Immunology Today 4:72; Cole et al. (1983) Proc. Natl. Acad. Sci. USA 80:2026-2030, and the EBV- hybridoma technique (Cole et al. (1985) Monoclonal Antibodies And Cancer Therapy, Alan R.
  • Such antibodies may be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD and any subclass thereof.
  • the hybridoma producing the mAb of this invention may be cultivated in vitro or in vivo.
  • a mouse or other appropriate host animal such as hamster or macaque monkey, is immunized as herein above described to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the antigen used for immunization.
  • lymphocytes may be immunized in vitro.
  • Lymphocytes are then fused with myeloma cells using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell.
  • a suitable fusing agent such as polyethylene glycol
  • the hybridoma cells thus prepared are seeded and grown in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, parental myeloma cells.
  • a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, parental myeloma cells.
  • the culture medium for the hybridoma typically will include hypoxanthine, aminopterin, and thymidine (HAT medium), which substances prevent the growth of HGPRT-deficient cells.
  • HAT medium hypoxanthine, aminopterin, and thymidine
  • Preferred meyloma cells are those that fuse efficiently, support stable high-level production of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium.
  • preferred myeloma cell lines are murine myeloma lines, such as those derived from MOP- 21 and M.C.- 1 mouse tumors, SP-2 or X63-Ag8-653 cells available from the American Typeure Collection (ATCC), RockviUe, MD.
  • Murine myeloma lines such as those derived from MOP- 21 and M.C.- 1 mouse tumors, SP-2 or X63-Ag8-653 cells available from the American Typeure Collection (ATCC), RockviUe, MD.
  • ATCC American Typeure Collection
  • RockviUe RockviUe
  • Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies.
  • Culture medium in which hybridoma cell are growing is assayed for production of monoclonal antibodies directed against CCR5 Loop 6 antigen.
  • the binding specificity of monoclonal antibodies produced by hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA).
  • RIA radioimmunoassay
  • ELISA enzyme-linked immunoabsorbent assay
  • hybridoma cells After hybridoma cells are identified that produce antibodies of the desired specificity, affinity, and/or activity, the clones may be subcloned by limiting dilution procedures and grown by standard methods. Suitable culture media for this purpose include, for example, DEME or RPMI-1640 medium. In addition, hybridoma cell may be grown in vivo as ascites tumors in an animal.
  • the monoclonal antibodies secreted by the subclones are suitably separated from the culture medium, ascites fluid, or serum, by conventional immunoglobulin purification procedures such as protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.
  • DNA encoding the monoclonal antibodies is readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the monoclonal antibodies).
  • the hybridoma cells serve as a preferred source of such DNA.
  • the DNA may be placed into expression vectors, which are then transferred into host cell such as E. coli cells, simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells.
  • Monoclonal antibodies against CCR5 Loop 6 may also be generated by using bacteriophage display.
  • Combinatorial libraries of antibodies have been generated in bacteriophage lambda expression systems which are screened as bacteriophage plaques or as colonies of lysogens (Huse et al. (1989) Science
  • a phage library is created by inserting a library of a random oligonucleotide or a cDNA library encoding antibody fragment such as V and VH into gene 3 of M 3 or fd phage. Each inserted gene is expressed at the N- terminal of the gene 3 product, a minor coat protein of the phage.
  • peptide libraries that contain diverse peptides can be constructed.
  • the phage library is then affinity screened against immobilized target molecule of interest, such as a peptide comprising a portion of CCR5 Loop6 or its fusion with a chaperon protein, and specifically bound phages are recovered and amplified by infection into Escherichia coli host cells.
  • the target molecule of interest such as a peptide comprising a portion of CCR5 Loop6 or its fusion with a chaperon protein (e.g., Gal4 DNA binding domain) is immobilized by covalent linkage to a chromatography resin to enrich for reactive phage by affinity chromatography) and/or labeled for screen plaques or colony lifts. This procedure is called biopanning.
  • amplified phages can be sequenced for deduction of the specific antibody sequences.
  • techniques developed for the production of "chimeric antibodies” or "humanized antibodies” may be utilized to modify mouse monoclonal antibodies to reduce immunogenicity of non-human antibodies. Morrison et al. (1984) Proc. Natl. Acad. Sci.
  • Such antibodies are generated by splicing the genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used.
  • a chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region.
  • single chain antibodies can be adapted to produce differentially expressed or pathway gene-single chain antibodies.
  • Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide.
  • Antibody fragments which recognize specific epitopes may be generated by known techniques.
  • such fragments include but are not limited to: the F(ab') 2 fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the F(ab') 2 fragments.
  • Fab expression libraries may be constructed (Huse et al. (1989) Science 246:1275-1281) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity.
  • FIG. 7 shows a homology alignment of the amino acid sequences of the three scFv antibodies.
  • FIG 7 shows a homology alignment of the amino acid sequences of the three scFv antibodies.
  • mutants of the three antibodies may be generated while conserving the consensus sequences in the heavy and/or light chain CDR2 regions.
  • an antibody that binds to loop 6 of human CCR5.
  • the antibody is capable of inhibiting HIV-1 infection of human cells.
  • CDR2 of the heavy chain variable region of the antibody comprises amino acid sequence GSTX-iYNPSL [SEQ ID NO: 32], wherein X 1 is asparagine (N) or threonine (T).
  • CDR2 of the light chain variable region comprises amino acid sequence DAX 2 X 3 L [SEQ ID NO: 33], wherein X 2 is threonine (T) or serine (S), and X 3 is threonine (T) or aspartic acid (D).
  • CDR2 of the heavy chain variable region of the antibody comprises amino acid sequence GSTX-,YNPSL [SEQ ID NO: 32]; and CDR2 of the light chain variable region comprises amino acid sequence DAX 2 X 3 L [SEQ ID NO: 32];
  • X 1 is asparagine (N) or threonine (T)
  • X 2 is threonine (T) or serine (S)
  • Xs is threonine (T) or aspartic acid (D).
  • CDR3 of the heavy chain variable region of the monoclonal antibody comprises 5, 6, 7, 8, 9 or more consecutive amino acids of a sequence elected from the group consisting of
  • CDR3 of the light chain variable region of the monoclonal antibody comprises 5, 6, 7, 8, 9 or more consecutive amino acids of a sequence elected from the group consisting of
  • CDR3 of the heavy chain variable region of the monoclonal antibody comprises an amino acid sequence selected from the group consisting of SEQ ID Nos: 43-45; and CDR3 of the light chain variable region of the monoclonal antibody comprises an amino acid sequence selected from the group consisting of SEQ ID Nos: 46-48.
  • the heavy chain variable region of the monoclonal antibody comprises an amino acid sequence selected from SEQ ID Nos: 36, 38, and 40 (shown in Figure 8).
  • the light chain variable region of the monoclonal antibody comprises an amino acid sequence selected from SEQ ID Nos: 37, 39, and 41 (shown in Figure 8).
  • conservative amino acid changes may be made, which although they alter the primary sequence of the peptide, do not normally alter its function.
  • Conservative amino acid substitutions typically include substitutions within the following groups:
  • Modifications of the antibodies include in vivo, or in vitro chemical derivatization of proteins, e.g., acetylation, or carboxylation. Also included are modifications of glycosylation, e.g., those made by modifying the glycosylation patterns of a protein during its synthesis and processing or in further processing steps; e.g., by exposing the protein to enzymes which affect glycosylation, e.g., mammalian glycosylating or deglycosylating enzymes. Also embraced are sequences which have phosphorylated amino acid residues, e.g., phosphotyrosine, phosphoserine, or phosphothreonine.
  • modifications of glycosylation e.g., those made by modifying the glycosylation patterns of a protein during its synthesis and processing or in further processing steps; e.g., by exposing the protein to enzymes which affect glycosylation, e.g., mammalian glycosylating or deg
  • proteins which have been modified using ordinary molecular biological techniques so as to improve their resistance to proteolytic degradation or to optimize solubility properties.
  • Analogs of such proteins include those containing residues other than naturally occurring L-amino acids, e.g., D- amino acids or non-naturally occurring synthetic amino acids.
  • the proteins of the invention are not limited to products of any of the specific exemplary processes listed herein.
  • the antibodies of the present invention selected against target peptides derived from HIV coreceptors may be used for prevention and treatment of HIV infection in vitro and in vivo.
  • cells are treated with the antibody of the invention, or a derivative thereof, either prior to or concurrently with the addition of virus.
  • Inhibition of infection of the cells by the antibody of the present invention is assessed by measuring the replication of virus in the cells, by identifying the presence of viral nucleic acids and/or proteins in the cells, for example, by performing PCR, Southern, Northern or Western blotting analyses, reverse transcriptase (RT) assays, or by immunofluorescence or other viral protein detection procedures.
  • the amount of antibody and virus to be added to the cells will be apparent to one skilled in the art from the teaching provided herein.
  • the antibody of the present invention is administered to a human subject who is either at risk of acquiring HIV infection, or who is already infected with HIV.
  • the antibody of the present invention may be formulated for delivery via various routes of administration, including but not limited to, orally, parenterally, intraperitoneally, intravenously, intraarterially, topically, transdermally, sublingually, intramuscularly, rectally, transbuccally, intranasally, liposomally, via inhalation, vaginally, intraoccularly, via local delivery (for example by catheter or stent), subcutaneously, intraadiposally, intraarticularly, or intrathecally.
  • the antibody is in an injectable formulation.
  • the formulation is suitable for parenteral administration by injection, e.g., by bolus injection or continuous infusion.
  • Formulations for injection may be presented in unit dosage form, e.g., in ampules or in multidose containers, with an added preservative.
  • the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
  • the antibody Prior to administration, the antibody, or a derivative thereof, is suspended in a pharmaceutically acceptable formulation such as a saline solution or other physiologically acceptable solution which is suitable for the chosen route of administration and which will be readily apparent to those skilled in the art of antibody preparation and administration.
  • a pharmaceutically acceptable formulation such as a saline solution or other physiologically acceptable solution which is suitable for the chosen route of administration and which will be readily apparent to those skilled in the art of antibody preparation and administration.
  • the dose of antibody to be used may vary dependent upon any number of factors including the age of the individual, the route of administration and the extent of HIV infection in the individual.
  • the antibody is prepared for administration by being suspended or dissolved in a pharmaceutically acceptable carrier such as saline, salt solution or other formulations apparent to those skilled in such administration.
  • the antibody is administered in a range of 0.1 ⁇ g to 1 g of protein per dose. Approximately 1-10 doses are administered to the individual at intervals ranging from once per day to once every few years.
  • the antibody may optionally be administered orally to a human.
  • the antibody of the present invention would be formulated in propylene glycol solution by attaching the antibody a polymer carrier.
  • Polymers or liposomes can stabilize the protein and desensitize it to digestive enzymes by encapsulating the protein within.
  • the antibody may be formulated for pulmonary delivery via inhalation.
  • the antibody could be delivered as aerosolized powder to a host using an inhaler.
  • the lung provides an excellent site for delivery of protein or peptide drug because the drugs are absorbed quickly into the blood-stream due to the huge surface area of the lung.
  • the layer separating airflow from blood vessels is very narrow, so that the drug does not have far to travel to enter blood.
  • the antibody of the invention may be administered to a host in a sustained release formulation using a biodegradable biocompatible polymer, or by on-site delivery using micelles, gels and liposomes, or rectally (e.g., by suppository or enema).
  • the antibody is formulated with a polymer such as pluronic F127.
  • the gel formulation may be injected subcutaneously or intramuscularly to allow the antibody to be bled out over a period of time to ensure efficacy.
  • the antibody of the invention may be administered to a host in a topical formulation.
  • the antibody may be formulated with suitable pharmaceutically acceptable carrier that does not denature or inactivate the protein in the form of lotion, cream, gel or suppository.
  • the anti- human CCR5 antibody of the present invention may be used as prophylactic or therapeutic to prevent or treat infection of HIV (or other sexually transmitted diseases or STD) via skin or mucosa of the body.
  • the topical formulation of the antibody may be applied to all areas of skin likely to come in intimate contact during sexual activity, especially to any area that has sores or breaks in the skin.
  • cream or lotion containing the antibody may be applied to the surfaces of the penis, the base of the penis and scrotum, the upper vagina, the inner and outer lips of the vulva, the inner thighs, pubic and perianal regions.
  • the antibody may also be applied to the anus and/or delivered directly to the rectum via the penis.
  • the antibody may be incorporated into an intrauterine device or an intravaginal device that timely releases the antibody into the uterus or into the vagina to provide continuous protection against infection of viruses.
  • the antibody may be formulated as copolymer with ethylene-vinyl acetate which forms a soft, rubber-like material. The procedures for forming an antibody co-polymer with ethylene-vinyl acetate are described in U.S. Patent No: 4,391 ,797 which is incorporated herein by reference in its entirety.
  • Applying the antibody to the skin and mucosa of the body is advantageous in that the surfaces of skin and mucus epithelia that are exposed to semen and other body fluids during sexual activity are most at risk of exposure to HIV or other STD pathogens. It is believed that the major roles of secreted antibodies are to block the adhesive groups that enable a pathogen to adhere to its target cell.
  • the antibody of the present invention can be used to block the adhesion of HIV to its target cells such as CD4 + cells by binding to HIV coreceptor such as CCR5 and CXCR4. With the occupation of the antibody on the coreceptors on the host's cells, HIV carried by body fluid such as semen and blood of another individual can be prevented from entry into the host's cells, thus significantly reducing the risk of infection.
  • Anti- retroviral drugs include many small molecule drugs (e.g. organic compounds) and macromolecule drugs (antisense DNAs/RNAs, ribozymes, viral surface protein-binding proteins or nucleotides, etc.).
  • Anti-retroviral drugs against HIV have been developed since the discovery of correlation between HIV and AIDS.
  • many anti- retroviral drugs have been developed to target critical enzymes of refroviruses and inhibit replication of the virus inside the host cell.
  • nucleoside or nucleotide analogs such as AZT, dideoxycytidine (ddC), and dideoxyinosine (ddl) were developed to inhibit reverse transcriptase (RT) of refroviruses by acting as competitive inhibitors and chain terminators.
  • Non-nucleoside or nucleotide inhibitors have also been found to inhibit reverse transcriptase activity of refroviruses by exerting an allosteric effect by binding to a hydrophobic pocket close to the active site of RT.
  • the protease (PRO) inhibitors in current use are targeted at the active site of the enzyme.
  • other classes of antiviral agents targeting different components of HIV or interfering with different stages of HIV life cycle may be also be used in conjunction with the antibody to achieve efficacious clinical results.
  • synthetic peptides have been modeled to mimic the coiled-coiled helical bundle formed by heptad repeat sequences of one of the two subunits of HIV envelop glycoprotein, the transmembrane glycoprotein (gp41).
  • heptad repeat sequences of one of the two subunits of HIV envelop glycoprotein, the transmembrane glycoprotein (gp41).
  • Wild C. T. et al. "A synthetic peptide inhibitor of HIV replication: correlation between solution structure and viral inhibition" Proc. Natl. Acad. Sci. USA 89: 10537-10541 (1992).
  • These heptad sequences play important roles in the conformational changes essential for membrane fusion of HIV with host cells.
  • DP178 have been shown to inhibit infection in vitro by disrupting the gp41 conformational changes associated with membrane fusion.
  • Wild, C. et al. "Peptides corresponding to a predictive alpha-helical domain of HIV-1 gp41 are potent inhibitors of virus infection" Proc. Natl. Acad. Sci. USA 91: 9770-9774 (1994).
  • a 36-amino acid peptide (T-20) corresponding to DP178, functions as a potent inhibitor of the HIV-1 envelop-cell membrane fusion and viral entry.
  • Wild, C. et al. "A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion" AIDS Res. Hum.
  • T-20 demonstrated potent antiviral activity in vivo when administered as an intravenous subcutaneous infusion in trials of 28 days or less.
  • Lalezari, J. et al Safety, pharmacokinetics, and antiviral activity of T-20 as a single agent in heavily pretreated patients" 6 th
  • Such inhibitors of HIV fusion and entry into the host cells may be combined with the antibodies of the present invention, as well as other anti-retroviral agents to inhibit HIV infection at different stages of the retroviral life cycle.
  • inhibitors of retroviral integrase may be used in conjunction with in combination with the antibodies of the present invention according to the present invention.
  • a variety of inhibitors of HIV integrase have been identified that inhibit HIV integration at different stages.
  • retroviral integration occurs in the following three biochemical stages: 1) assembly of a stable complex with specific DNA sequences at the end of the HIV-1 long terminal repeat (LTR) regions, (2) endonucleolytic processing of the viral DNA to remove the terminal dinucleotide from each 3' end, and (3) strand transfer in which the viral DNA 3' ends are covalently linked to the cellular (target) DNA.
  • LTR long terminal repeat
  • the most potent and specific compounds each contained a distinct diketo acid moiety, such as compound L-731,988, L-708,906, L-731,927, and L- 731,942. Hazuda, D. J. et al. (2000), supra.
  • Such inhibitors of HIV integration into the host genome may be combined with in combination with the antibodies of the present invention, as well as other anti-retroviral agents to inhibit HIV infection at different stages of the retroviral life cycle.
  • nucleoside reverse transcriptase inhibitors are the preferred anti-retroviral drugs in combination with the antibody.
  • nucleoside HIV reverse transcriptase inhibitors include, but are not limited to zidovudine (AZT), didanosine (ddl), zalcitabine (ddC), lamivudine (3TC), stavudine (d4T), abacavir (1592U89), and adefovir dipivoxil (bis(POM)-PMEA).
  • non-nucleoside HIV reverse transcriptase inhibitor examples include, but are not limited to nevirapine (BI-RG-587), delavirdine (BHAP, U-90152) and efavirenz (DMP 266).
  • HIV protease inhibitors include, but are not limited to indinavir (MK-639), ritonavir (ABT-538), saqinavir (Ro-31-8959), nelfinavir (AG-1343), and amprenavir (141W94).
  • the antibody of the present invention may be used in combination with any one or more of the antiretroviral drugs, preferably with a "cocktail" of nucleoside reverse transcriptase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, and protease inhibitors.
  • the antibody of the present invention may be combined with two nucleoside reverse transcriptase inhibitors (e.g. zidovudine (AZT) and lamivudine (3TC)), and one protease inhibitor (e.g. indinavir (MK-639)).
  • the antibody of the present invention may also be combined with one nucleoside reverse transcriptase inhibitor (e.g.
  • the antibody of the present invention may be combined with one nucleoside reverse transcriptase inhibitor (e.g. zidovudine
  • AKT nelfinavir
  • saqinavir Ro- 31-8959
  • the pharmaceutical composition of the present invention further includes one or more general antiviral agents.
  • general antiviral agents include, but are not limited to acyclovir, ganciclovir, trisodium phosphonoformate, novapren (Novaferon Labs, Inc., Akron, OH), Peptide T Octapeptide Sequence (Peninsula Labs, Belmont, CA), ansamycin LM 427 (Adria Labortories, Dublin, OH), dextran sulfate, virazole, ribavirin (Virateck/ICN, Costa Mesa, CA), ⁇ -interferon, and ⁇ -interferon.
  • General antiviral agents can be used to prevent or inhibit opportunistic infections of other viruses. 4. Use of antibody against HIV coreceptors for screening anti-HIV agents
  • the antibody of the present invention may also be used in a method of screening agents for anti-HIV activity.
  • a test agent e.g., a compound
  • Compounds which bind to the antibody are likely to share structural and perhaps biological activities with the HIV coreceptor (e.g., CCR5) and thus, may serve as competitive inhibitors for inhibition of the interaction of HIV envelope protein with CD4 and/or CCR5 plus CD4.
  • An antibody-binding compound is further tested for antiviral activity by treating cells with the compound either prior to or concurrently with the addition of virus to the cells. Alternatively, the virus and the compound may be mixed together prior to the addition of the mixture to the cells.
  • the ability of the compound to affect virus infection is assessed by measuring virus replication in the cells using any one of the known techniques, such as a RT assay, immunofluorescence assays and other assays known in the art useful for detection of viral proteins or nucleic acids in cells. Generation of newly replicated virus may also be measured using known virus assays such as those which are described herein.
  • the antibody of the present invention may also be used in competition assays to screen for compounds that bind to the HIV coreceptor (e.g., CCR5) and which therefore prevent binding of the antibody to the coreceptor. Such compounds, once identified, may be examined further to determine whether or not they prevent entry of virus into cells. Compounds which prevent entry of virus into cells are useful as anti-viral compounds. Additional uses for the antibody of the present invention include the identification of cells in the body which are potential targets for infection by HIV. These cells express HIV coreceptor(s) and are therefore capable of being infected by HIV. For example, cells which are potential targets for HIV infection may be identified by virtue of the presence of CCR5 on their surface. The antibody of the present invention facilitates identification of these cells as follows.
  • the antibody of the present invention is first combined with an identifiable marker, such as an immunofluorescent or radioactive marker. Cells which are obtained from a human subject are then reacted with the tagged antibody. Binding of the antibody to cells is an indication that such cells are potential targets for HIV infection.
  • the identification of cells which may be infected with HIV is important for the design of therapies for the prevention of HIV infection. In the case of individuals who are infected with HIV, the identification of target cells provides an immune profile of these individuals which provides useful information regarding the progress of their infection.
  • the antibody may be useful for the detection of CCR5 on a variety of cell types on which CCR5 may be expressed.
  • the monoclonal antibody of the present invention may be useful for monitoring CCR5 expression levels on a variety of cell types, which expression may be an indication of a disease state in a human, including, but not limited to
  • HIV infection HIV infection, atherosclerosis, and the like.
  • the library of scFv proteins may be produced in vivo or in vitro by using any methods known in the art.
  • the library of scFv proteins is constructed in yeast by exploiting the intrinsic property of yeast — homologous recombination at an extremely high level of efficiency.
  • FIG. 3 shows a flow chart delineating a method for generating and screening highly diverse libraries of single-chain human antibodies (scFv) in yeast.
  • a highly complex library of scFv is constructed in yeast cells.
  • cDNA libraries of the heavy and light chain variable regions (VH and Vi.) are transferred into a yeast expression vector by direct homologous recombination between the sequences encoding VH and V L , and the yeast expression vector containing homologous recombination sites.
  • the resulting expression vector is called scFv expression vector.
  • This primary antibody library may reach a diversity preferably between 10 6 -10 12 , more preferably between 10 7 -10 12 , and most preferably between 10 8 -10 12 .
  • the diversity of V H and V L within the library of scFv fusion proteins may be preferably between 10 3 -10 8 , more preferably between 10 4 -10 8 , and most preferably between 10 5 -10 8 .
  • AD is an activation domain of yeast GAL 4 transcription activator
  • BD is a DNA binding domain of yeast GAL 4 transcription activator
  • the linker sequence L may have a specific sequence, or vary within the library of the yeast expression vectors.
  • the linker sequences L in the library of expression vectors is preferably between 30-120 bp in length, more preferably between 45-102 bp in length, and most preferably between 45-63 bp in length.
  • the linker sequence in the library of expression vectors preferably comprises a nucleotide sequence encoding an amino acid sequence of Gly-Gly-Gly-Gly-Ser in 3 or 4 tandem repeats.
  • the linker peptides expressed by the library of expression vectors preferably provide a substantially conserved conformation between the first and second polypeptide subunits across the fusion proteins expressed by the library of expression vectors.
  • a linker peptide Gly-Gly-Gly-Gly-Ser [SEQ ID NO: 42] in 4 tandem repeats (G S) 4 [SEQ ID NO: 4] is believed to provide a substantially conserved conformation of scFv antibodies which preserves its antigen-binding site in the variable regions of the corresponding full antibody.
  • DNA sequences encoding human antibody VH and V segments may be polynucleotide segments of at least 30 contiguous base pairs substantially encoding genes of the immunoglobulin superfamily.
  • the VH and VL genes are most frequently encoded by human, non-human primate, avian, porcine, bovine, ovine, goat, or rodent heavy chain and light chain gene sequences.
  • the library of DNA sequences encoding human antibody VH and V segments may be derived from a variety of sources.
  • mRNA encoding the human antibody VH and VL libraries may be extracted from cells or organs from immunized or non-immunized animals or humans.
  • organs such as human fetal spleen and lymph nodes may be used.
  • Peripheral blood cells from non-immunized humans may also be used.
  • the blood samples may be from an individual donor, from multiple donors, or from combined blood sources.
  • the human antibody VH - and V -coding sequences may be derived and amplified by using sets of oligonucleotide primers to amplify the cDNA of human heavy and light chains variable domains by polymerase chain reaction (PCR).
  • PCR polymerase chain reaction
  • RNA can be prepared by following standard procedures. Cathala et al. (1983) DNA 3:329. The cDNA can be made from the isolated RNA by using reverse transcriptase.
  • the VH - and V -coding sequences may be derived from an artificially rearranged immunoglobulin gene or genes.
  • immunoglobulin genes may be rearranged by joining of germ line V segments in vitro to J segments, and, in the case of VH domains, D segments. The joining of the V, J and D segments may be facilitated by using PCR primers which have a region of random or specific sequence to introduce artificial sequence or diversity into the products.
  • the fusion protein formed by linking VH and V polypeptides is also referred as a single-chain antibody, scFv.
  • a typical scFv comprises a VH domain and a VL domain in polypeptide linkage, generally linked via a spacer/linker peptide L.
  • the linker peptide sequence L may encode an appropriately designed linker peptide, such as (Gly-Gly-Gly-Gly-Ser) 4 [SEQ. ID
  • linker bridges the C-terminus of the first V region and N-terminus of the second, ordered as either VH-L-VLO ⁇ VL-L-
  • a scFv may comprise additional amino acid sequences at the amino- and/or carboxy-termini.
  • a single-chain antibody may comprise a tether segment for linking to the constant regions of a complete or full antibody.
  • a functional single-chain antibody generally contains a sufficient portion of an immunoglobulin superfamily gene product so as to retain the property of binding to a specific target molecule, typically a receptor or antigen (epitope).
  • the expression vector is based on a yeast plasmid, especially one from Saccharomyces cerevisiae. After transformation of yeast cells, the exogenous DNA encoding scFv fusion proteins are uptaken by the cells and subsequently expressed by the transformed cells.
  • the expression vector may be a yeast-bacteria shuttle vector which can be propagated in either Escherichia coli or yeast Struhl, et al.
  • E. coli plasmid DNA sequences such as pBR322
  • pBR322 E. coli plasmid DNA sequences
  • yeast plasmid vector that may serve as the shuttle may be a replicating vector or an integrating vector.
  • a replicating vector is yeast vector that is capable of mediating its own maintenance, independent of the chromosomal DNA of yeast, by virtue of the presence of a functional origin of DNA replication.
  • An integrating vector relies upon recombination with the chromosomal DNA to facilitate replication and thus the continued maintenance of the recombinant DNA in the host cell.
  • a replicating vector may be a 2 ⁇ - based plasmid vector in which the origin of DNA replication is derived from the endogenous 2 ⁇ plasmid of yeast.
  • the replicating vector may be an autonomously replicating (ARS) vector, in which the "apparent" origin of replication is derived from the chromosomal DNA of yeast.
  • the replicating vector may be a centromeric (CEN) plasmid which carries in addition to one of the above origins of DNA replication a sequence of yeast chromosomal DNA known to harbor a centromere.
  • the vectors may be transformed into yeast cells in a closed circular form or in a linear form. Transformation of yeast by integrating vectors, although with inheritable stability, may not be efficient when the vector is in in a close circular form (e.g. 1-10 transformants per ug of DNA). Linearized vectors, with free ends located in DNA sequences homologous with yeast chromosomal DNA, transforms yeast with higher efficiency (100-1000 fold) and the transforming DNA is generally found integrated in sequences homologous to the site of cleavage. Thus, by cleaving the vector DNA with a suitable restriction endonuclease, it is possible to increase the efficiency of transformation and target the site of chromosomal integration. Integrative transformation may be applicable to the genetic modification of brewing yeast, providing that the efficiency of transformation is sufficiently high and the target DNA sequence for integration is within a region that does not disrupt genes essential to the metabolism of the host cell.
  • ARS plasmids which have a high copy number (approximately 20-50 copies per cell) (Hyman et al., 1982), tend to be the most unstable, and are lost at a frequency greater than 10% per generation.
  • the stability of ARS plasmids can be enhanced by the attachment of a centromere; centromeric plasmids are present at 1 or 2 copies per cell and are lost at only approximately
  • the expression vector of the present invention is preferably based on the 2 ⁇ plasmid.
  • the 2 ⁇ plasmid is known to be nuclear in cellular location, but is inherited in a non-Mendelian fashion. Cells that lost the 2 ⁇ plasmid have been shown to arise from haploid yeast populations having an average copy number of 50 copies of the 2 ⁇ plasmid per cell at a rate of between 0.001% and 0.01% of the cells per generation. Futcher & Cox (1983) J. Bacteriol. 154:612. Analysis of different strains of S. cerevisiae has shown that the plasmid is present in most strains of yeast including brewing yeast. The 2 ⁇ plasmid is ubiquitous and possesses a high degree of inheritable stability in nature.
  • the 2 ⁇ plasmid harbors a unique bidirectional origin of DNA replication which is an essential component of all 2 ⁇ - based vectors.
  • the plasmid contains four genes, REP1, REP2, REP3 and FLP which are required for the stable maintenance of high plasmid copy number per cell Jaysram et al. (1983) Cell 34:95.
  • the REP1 and REP2 genes encode trans-acting proteins which are believed to function in concert by interacting with the REP3 locus to ensure the stable partitioning of the plasmid at cell division.
  • the REP3 gene behaves as a cis acting locus which effects the stable segregation of the plasmid, and is phenotypically analogous to a chromosomal centromere.
  • An important feature of the 2 ⁇ plasmid is the presence of two inverted DNA sequence repeats (each 559 base-pairs in length) which separate the circular molecule into two unique regions. Intramolecular recombination between the inverted repeat sequences results in the inversion of one unique region relative to the other and the production in vivo of a mixed population of two structural isomers of the plasmid, designated A and B. Recombination between the two inverted repeats is mediated by the protein product of a gene called the FLP gene, and the FLP protein is capable of mediating high frequency recombination within the inverted repeat region. This site specific recombination event is believed to provide a mechanism which ensures the amplification of plasmid copy number.
  • the expression vector may also contain an Escherichia coli origin of replication and E. coli antibiotic resistance genes for propagation and antibiotic selection in bacteria.
  • Escherichia coli origin of replication and E. coli antibiotic resistance genes for propagation and antibiotic selection in bacteria.
  • E. co// ' origins are known, including ColE1 , pMB1 and pBR322, The ColE origin of replication is preferably used in this invention.
  • E. coli drug resistance genes are known, including the ampicillin resistance gene, the chloramphenoicol resistance gene and the tetracycline resistance gene. In one particular embodiment, the ampicillin resistance gene is used in the vector.
  • the transformants that carry the scFv library may be selected by using various selection schemes.
  • the selection is typically achieved by incorporating within the vector DNA a gene with a discernible phenotype.
  • prototrophic genes such as LEU2, URA3 or TRPI, are usually used to complement auxotrophic lesions in the host.
  • LEU2, URA3 or TRPI prototrophic genes
  • replicating transformants carrying 2 ⁇ -based plasmid vectors may be selected based on expression of marker genes which mediate resistance to: antibiotics such as G418, hygromycin B and chloramphenicol, or otherwise toxic materials such as the herbicide sulfometuron methyl, compactin and copper.
  • the present invention provides efficient methods for screening the scFv library against any target peptide in a yeast two-hybrid system.
  • the two-hybrid system is a selection scheme designed to screen for polypeptide sequences which bind to a predetermined polypeptide sequence present in a fusion protein.
  • This approach identifies protein-protein interactions in vivo through reconstitution of a transcriptional activator.
  • Fields and Song (1989) Nature 340: 245) the yeast Gal 4 transcription protein.
  • the method is based on the properties of the yeast Gal 4 protein, which consists of separable domains responsible for DNA-binding and transcriptional activation.
  • Polynucleotides encoding two hybrid proteins, one consisting of the yeast Gal 4 DNA-binding domain (BD) fused to a polypeptide sequence of a known protein and the other consisting of the Gal4 activation domain (AD) fused to a polypeptide sequence of a second protein, are constructed and introduced into a yeast host cell.
  • BD yeast Gal 4 DNA-binding domain
  • AD Gal4 activation domain
  • the two fusion proteins reconstitutes the Gal4 DNA-binding domain with the Gal4 activation domain, which leads to the transcriptional activation of a reporter gene (e.g., lacZ, HIS3) which is operably linked to a Gal4 binding site.
  • a reporter gene e.g., lacZ, HIS3
  • the two-hybrid method is used to identify novel polypeptide sequences which interact with a known protein. Silver and Hunt (1993) Mol. Biol. Rep. 17: 155; Durfee et al. (1993) Genes Devel. 7; 555; Yang et ai. (1992) Science 257: 680; Luban et al. (1993) Cell 73: 1067; Hardy et al. (1992) Genes Devel.
  • the two-hybrid system was used to detect interactions between three specific single-chain variable fragments (scFv) and a specific antigen. De Jaeger et al. (2000) FEBS Lett. 467:316-320. The two-hybrid system was also used to screen against cell surface proteins or receptors such as receptors of hematopoietic super family in yeast. Ozenberger, B. A., and Young, K. H.
  • selection of binding protein using a two-hybrid method relies upon a positive association between two Gal4 fusion proteins, thereby reconstituting a functional Gal4 transcriptional activator which then induces transcription of a reporter gene operably linked to a Gal4 binding site.
  • Transcription of the reporter gene produces a positive readout, typically manifested either (1) as an enzyme activity (e.g., ⁇ -galactosidase) that can be identified by a colorimetric enzyme assay or (2) as enhanced cell growth on a defined medium (e.g., HIS3 and Ade 2).
  • a defined medium e.g., HIS3 and Ade 2
  • Various procedures have developed to reduce and eliminate the false positive clones from the final positives. For example, 1) prescreening the clones that contains the target vector and shows positive in the absence of the two-hybrid partner (Bartel, P. L., et al. (1993) "Elimination of false positives that arise in using the two-hybrid system"
  • BioTechniques 14:920-924 2) by using multiple reporters such as His3, ⁇ - galactosidase, and Ade2 (James, P. et al. (1996) "Genomic libraries and a host strain designed for highly efficient two-hybrid selection in yeast” Genetics 144:1425-1436); 3) by using multiple reporters each of which is under different GAL 4 -responsive promoters such as those in yeast strain Y190 where each of the His 3 and ⁇ -Gal reporters is under the control of a different promoter Gal 1 or Gal 10, but both response to Gal 4 signaling (Durfee, T., et al (1993) "The retinoblastoma protein associates with the protein phosphatase type 1 catalytic subunit" Genes Devel.
  • the false positive clones may also be eliminated by using unrelated targets to confirm specificity. This is a standard control procedure in the two-hybrid system which can be performed after the library isolate is confirmed by the above-described 1)-4) procedures.
  • the library clones are confirmed by co-transforming the initially isolated library clones back into the yeast reporter strain with one or more control targets unrelated to the target used in the original screening. Selection is conducted to eliminate those library clones that show positive activation of the reporter gene and thus indicate non- specfic interactions with multiple, related proteins.
  • the scFv fusion protein When the library of scFv fusion proteins are expressed by the expression vector in yeast cells, such as cells from the Saccharomyces cerevisiae strains, the scFv fusion protein undergoes a process of protein folding to adopt one or more conformations.
  • the peptide sequence encoded by the linker sequence L also facilitates the folding by providing a flexible hinge between the V H and V L .
  • the conformation(s) adopted by the scFv fusion protein may have suitable binding site(s) for a specific target peptide expressed as fusion protein with the domain BD of a transcription activator.
  • the AD domain of the scFv fusion protein should be able to activate transcription of gene(s) once the AD and BD domains are reconstituted to form an active transcription activator in vitro or in vivo by a two-hybrid method.
  • the highly complex primary antibody libraries is screened against the peptide target, for example a 30 aa peptide derived from loop 6 of CCR5. This screening for antibody-antigen interaction is conveniently carried out in yeast by using a yeast two-hybrid method.
  • the library of scFv expression vectors are introduced into yeast cells.
  • scFv antibody library in the yeast cells produces a library of scFv fusion proteins, each fusion protein comprising a scFv and an activation domain (AD) of a transcription activator.
  • the yeast cells are also modified to express a recombinant fusion protein comprising a DNA-binding domain (BD) of the transcription activator and the target peptide.
  • the yeast cells are also modified to express a reporter gene whose expression is under the control of a specific DNA binding site.
  • the AD is brought into close proximity of BD, thereby causing transcriptional activation of a reporter gene downstream from a specific DNA binding site to which the BD binds.
  • the library of scFv expression vectors may contain the BD domain while the modified yeast cells express a fusion protein comprising the AD domain and the target peptide.
  • scFv expression vectors may be introduced to yeast cells by co- transformation of diploid yeast cells or by direct mating between two strains of haploid yeast cells.
  • the scFv expression vectors and an expression vector containing the target peptide can be used to co-transform diploid yeast cells in a form of yeast plasmid or bacteria-yeast shuttle plasmid.
  • two strains haploid yeast cells e.g. ⁇ - and a-type strains of yeast
  • each containing the scFv expression vector and the target peptide expression vector are mated to produce a diploid yeast cell containing both expression vectors.
  • the haploid yeast strain containing the target peptide expression vector also contains the reporter gene positioned downstream of the specific DNA binding site.
  • the yeast clones containing scFv antibodies with binding affinity to the target peptide are selected based on phenotypes of the cells or other selectable markers.
  • the plasmids encoding these primary antibody leads can be isolated and further characterized.
  • the affinity and biological activity of the primary antibody leads can be determined using assays particularly designed based on the specific target protein from which the target peptide is derived.
  • FIG. 2A illustrates a flow diagram of a preferred embodiment of the above described method.
  • the sequence library containing scFv fused with an AD domain upstream is carried by a library of expression vectors, the AD-scFv vectors.
  • the coding sequence of the target peptide (labeled as "Target") is contained in another expression vector and fused with a BD domain, forming the BD-Target vector.
  • the AD-scFv vector and the BD-Target vector may be co-transformed into a yeast cell by using method known in the art. Gietz, D. et ai. (1992)
  • the construct carrying the specific DNA binding site and the reporter gene may be stably integrated into the genome of the host cell or transiently transformed into the host cell.
  • Reporter the reporter gene
  • the library of scFv fusion proteins undergo protein folding in the host cell and adopt various conformations.
  • Some of the scFv fusion proteins may bind to the Target protein expressed by the BD-Target vector in the host cell, thereby bringing the AD and BD domains to a close proximity in the promoter region (i.e., the specific DNA binding site) of the reporter construct and thus reconstituting a functional transcription activator composed of the AD and BD domains.
  • the promoter region i.e., the specific DNA binding site
  • AD activates the transcription of the reporter gene downstream from the specific DNA binding site, resulting in expression of the reporter gene, such as the lacZ reporter gene.
  • Clones showing the phenotype of the reporter gene expression are selected, and the AD-scFv vectors are isolated.
  • the coding sequences for scFv are identified and characterized.
  • the' steps of expressing the library of scFv fusion proteins and expressing the target fusion protein includes causing mating between first and second populations of haploid yeast cells of opposite mating types.
  • the first population of haploid yeast cells comprises a library of scFv expression vectors for the library of tester fusion proteins.
  • the second population of haploid yeast cells comprises a target expression vector.
  • Either the first or second population of haploid yeast cells comprises a reporter construct comprising the reporter gene whose expression is under transcriptional control of the transcription activator.
  • the haploid yeast cells of opposite mating types may preferably be ⁇ and a type strains of yeast.
  • the mating between the first and second populations of haploid yeast cells of ⁇ and a type strains may be conducted in a rich nutritional culture medium.
  • FIG. 2B illustrates a flow diagram of a preferred embodiment of the above described method.
  • the sequence library containing scFv fused with an AD domain upstream is carried by a library of expression vectors, the AD- scFv vectors.
  • the library of the AD- scFv vectors are transformed into haploid yeast cells such as the a type strain of yeast.
  • the coding sequence of the target protein (labeled as "Target”) is contained in another expression vector and fused with a BD domain, forming the
  • the BD-Target vector is transformed into haploid cells of opposite mating type of the haploid cells containing the the AD-scFv vectors, such as the ⁇ type strain of yeast.
  • the construct carrying the specific DNA binding site and the reporter gene (labeled as "Reporter") may be transformed into the haploid cells of either the type a or type ⁇ strain of yeast.
  • the haploid cells of the type a and type ⁇ strains of yeast are mated under suitable conditions such as low speed of shaking in liquid culture, physical contact in solid medium culture, and rich medium such as YPD.
  • suitable conditions such as low speed of shaking in liquid culture, physical contact in solid medium culture, and rich medium such as YPD.
  • Drosophila cell cycle regulators Proc. Natl. Acad. Sci. USA, 91 :12980-12984.
  • the AD-scFv, the BD-Target expression vectors and the Reporter construct are taken into the parental diploid cells of the a and type ⁇ strain of haploid yeast cells.
  • the library of scFv fusion proteins undergo protein folding in the host cell and adopt various conformations.
  • AD-scFv fusion proteins may bind to the Target protein expressed by the BD-Target vector in the parental diploid cell, thereby bringing the AD and BD domains to a close proximity in the promoter region (i.e., the specific DNA binding site) of the reporter construct and thus reconstituting a functional transcription activator composed of the AD and BD domains.
  • the AD activates the transcription of the reporter gene downstream from the specific DNA binding site, resulting in expression of the reporter gene, such as the lacZ reporter gene.
  • Clones showing the phenotype of the reporter gene expression are selected, and the AD-scFv vectors are isolated. The coding sequences for scFv are identified and characterized.
  • reporter genes may be used in the present invention.
  • proteins encoded by reporter genes include, but are not limited to, easily assayed enzymes such as ⁇ -galactosidase, ⁇ -galactosidase, luciferase, ⁇ -glucuronidase, chloramphenicol acetyl transferase (CAT), secreted embryonic alkaline phosphatase (SEAP), fluorescent proteins such as green fluorescent protein (GFP), enhanced blue fluorescent protein (EBFP), enhanced yellow fluorescent protein (EYFP) and enhanced cyan fluorescent protein (ECFP); and proteins for which immunoassays are readily available such as hormones and cytokines.
  • the expression of these reporter genes can also be monitored by measuring levels of mRNA transcribed from these genes.
  • certain reporter(s) are of nutritional reporter which allows the yeast to grow on the specific selection medium plate. This is a very powerful screening process, as has been shown by many published papers.
  • the nutritional reporter include, but are not limited to, His3, Ade2, Leu2, Ura3, Trp1 and Lys2.
  • His3 reporter is described in Bartel, P. L. et al. (1993) "Using the two-hybrid system to detect protein-protein interactions", in Cellular interactions in Development: A practical approach, ed. Hastley, D. A., Oxford Press, pages 153-179.
  • the Ade2 reporter is described in Jarves, P. et al. (1996) "Genomic libraries and a host strain designed for highly efficient two-hybrid selection in yeast” Genetics 144:1425-1436.
  • a library of scFv expression vectors that contains a scFv fused with an AD domain of GAL 4 transcription activator may be transformed into haploid cells of the ⁇ mating type of yeast strain.
  • a BD domain of GAL 4 transcription activator is fused with the sequence encoding the target protein to be selected against the scFV library in a plasmid. This plasmid is transformed into haploid cells of the a mating type of yeast strain.
  • Equal volume of AD-scFv library-containing yeast stain ( ⁇ -type) and the BD-target-containing yeast strain (a-type) are inoculated into selection liquid medium and incubated separately first. These two cultures are then mixed and allowed to grow in rich medium such as 1xYPD and 2xYPD. Under the rich nutritional culture condition, the two haploid yeast strains will mate and form diploid cells. At the end of this mating process, these yeast cells are plated into selection plates.
  • a multiple-marker selection scheme may be used to select yeast clones that show positive interaction between the scFVs in the library and the target. For example, a scheme of SD/-Leu-Trp- His-Ade may be used.
  • the first two selections are for markers (Leu and Trp) expressed from the AD-scFv library and the BD-Target vector, respectively.
  • markers Leu and Trp expressed from the AD-scFv library and the BD-Target vector, respectively.
  • diploid cells retaining both BD and AD vectors in the same yeast cells are selected.
  • His-Ade are used to screen for those clones that express the reporter gene from parental strain, presumably due to affinity binding between the scFv in the library and the target.
  • the putative interaction between the gene probe and the library clone isolates can be further tested and confirmed in vitro or in vivo.
  • In vitro binding assays may be used to confirm the positive interaction between the scFv expressed by the clone isolate and the target peptide.
  • the in vitro binding assay may be a "pull-down" method, such as using GST (glutathione S-transferase)-fused gene probe as matrix-binding protein, and with in vitro expressed library clone isolate that are labeled with a radioactive or non-radioactive group.
  • the in vitro binding assay may also be a Co- immuno-precipitation (Co-IP) method using two affinity tag antibodies.
  • Co-IP Co- immuno-precipitation
  • both the target gene probe and the library clone isolate are in vitro expressed fused with peptide tags, such as HA (haemaglutinin A) or Myc tags.
  • the gene probe is first immuno-precipitated with an antibody against the affinity peptide tag (such as HA) that the target gene probe is fused with. Then the second antibody against a different affinity tag (such as Myc) that is fused with the library clone isolate is used for reprobing the precipitate.
  • In vivo assays may also be used to confirm the positive interaction between the scFv expressed by the clone isolate and the target peptide.
  • a mammalian two-hybrid system may serve as a reliable verification system for the yeast two-hybrid library screening.
  • the target gene probe and library clone are fused with Gal 4 DNA-binding domain or an mammalian activation domain (such as VP-16) respectively.
  • These two fusion proteins under control of a strong and constitutive mammalian promoter (such as CMV promoter) are introduced into mammalian cells by transfection along with a reporter responsive to Gal 4.
  • the reporter can be CAT gene
  • the antibody library described above may be screened against a target peptide fragment derived from a membrane protein in other organisms or in vitro.
  • the target peptide may be expressed as a fusion protein with another protein and screened against the antibody library co-expressed in mammalian cells.
  • the target peptide may also be immobilized to a substrate as a single peptide or a fusion protein and selected against a library of antibodies displayed by bacteriophagedisplayed, mRNA, ribosome or cells such as yeast cells.
  • the target peptide may be introduced to a xenomouse, HuMab mouse, or a transchromosomal mouse which contains a library of human antibody, and selected for monoclonal human antibodies with specific binding affinity to target peptide and/or the target membrane protein.
  • the library of human antibodies may be screened against a target peptide derived from a membrane protein (e.g., CCR5) by using ribosome display.
  • Ribosome display is a form of protein display for in vitro selection against a target ligand.
  • mRNA encoding the tester protein e.g. an antibody
  • the translated tester protein are associated through the ribosome complex, also called an antibody-ribosome-mRNA (ARM) complex.
  • ARM antibody-ribosome-mRNA
  • He and Taussig (1997) Nucleic Acid Research 25:5132-5134.
  • the principle behind this approach is that single chain antibody can be functionally produced in an in vitro translation system (e.g.
  • each member of the library of human antibody sequences includes a bacterial phage T7 promoter and protein synthesis initiation sequence attached to the 5' end of the cDNA encoding the antibody (e.g., scFv) and no stop codon in the 3' end. Because the cDNA pool is depleted of the stop codon, when the mRNA is transcribed from the cDNA and is subject to in vitro translation, the mRNA will still be attached to the ribosome and mRNA, forming the ARM complex.
  • a bacterial phage T7 promoter and protein synthesis initiation sequence attached to the 5' end of the cDNA encoding the antibody (e.g., scFv) and no stop codon in the 3' end.
  • the library of human scFv antibody that is translated from the cDNA gene pool and displayed on the surface of the ribosome can be screened against the target peptide as a single peptide or as a fusion protein with a protein other than the target membrane protein.
  • the in vitro transcription and translation of this library may be carried out in rabbit reticulocyte lysate in the presence of methionine at 30°C by using the commercially available systems, such as TNT T7 Quick Coupled
  • the target peptide or its fusion protein may be immobilized to a solid substrate, such as a chromatography resin by covalent linkage to enrich for those ribosomes with high affinity humanized antibody attached.
  • a solid substrate such as a chromatography resin
  • affinity chromatography the ribosomes with high affinity scFv antibody attached are isolated.
  • the mRNA encoding the high affinity scFv antibody is recovered from the isolated ARM complexes and subject to reverse transcriptase (RT)/PCR to synthesize and amplify the cDNA of the selected antibody. This completes the first cycle of the panning process for antibody isolation and its coding sequence characterization. Such a panning process may be repeated until scFv antibody with desirably affinity is isolated.
  • the library of human antibodies may be screened against a target peptide derived from a membrane protein (e.g., CCR5) by using mRNA display.
  • a target peptide derived from a membrane protein e.g., CCR5
  • Wilson et al. 2001
  • Proc Natl Acad Sci USA. 98:3750-3755
  • Keefe and Szostak 2001
  • Nature 410:715-718 are incorporated by reference as if fully reproduced below.
  • Each of the antibodies can be covalently linked through the carboxy terminus if the antibody is a single chain antibody or through the carboxy terminus of the light or heavy chain if the antibody is a Fv, Fab or a fully assembled antibody to the 3' end of its encoding mRNA.
  • the target peptide or its fusion protein may be immobilized to a solid substrate, such as a chromatography resin by covalent linkage to enrich for the mRNA to which high affinity humanized antibody is linked.
  • a solid substrate such as a chromatography resin
  • the mRNA encoding the high affinity antibody is recovered from the isolated the mRNA-antibody conjugate and subject to reverse transcriptase (RT)/PCR to synthesize and amplify the cDNA of the selected antibody.
  • RT reverse transcriptase
  • the library of human antibodies may be screened against a target peptide derived from a membrane protein (e.g., CCR5) by using yeast display.
  • yeast display Boder et al. (2000) Proc Natl Acad Sci USA. 97:10701-10705; and Boder and Wittrup (1997) Nat Biotechnol. 15:553-557.
  • the library of antibodies may be display on the surface of yeast cells via C-terminal fusion to the Aga2p mating adhesion receptor of Saccharomyces cerevisiae. The displayed antibodies can be selected for binding to the target peptide or its fusion with a chaperon protein.
  • Such a eukaryotic host may alleviate expression biases present in bacterially propagated combinatorial libraries.
  • the target peptide or its fusion protein may be immobilized to a solid substrate or present in a solution.
  • the target peptide or its fusion may be mixed with yeast cells which display the library of antibodies on the cell surface.
  • the cell displaying the antibody that binds to the target may be selected by using flow cytometric cell sorting.
  • the cDNA encoding the selected antibody can be recovered from the isolated cell. This completes the first cycle of the selection process for antibody isolation and its coding sequence characterization. Such a selection process may be repeated until antibody with desirably affinity is isolated.
  • the binding affinity of the primary scFv antibody leads can be improved by using an in vitro affinity maturation process according to the present invention.
  • the coding sequences of these protein leads may be mutagenized in vitro or in vivo to generated a secondary library more diverse than these leads.
  • the mutagenized leads can be selected against the target peptide again in vivo following similar procedures described for the selection of the primary library carrying scFv.
  • Such mutagenesis and selection of primary antibody leads effectively mimics the affinity maturation process naturally occurring in a mammal that produces antibody with progressive increase in the affinity to the immunizing antigen.
  • VH and V of the primary antibody leads are mutagenized in vitro to produce a secondary antibody library.
  • the VH and VL sequences can be randomly mutagenized by "poison" PCR (or error-prone PCR), by DNA shuffling, or by any other way of random or site-directed mutagenesis (or cassette mutagenesis).
  • the secondary antibody library formed by the mutants of the primary antibody can be screened against the peptide target by using the yeast two- hybrid system or other screening method. Mutants with higher affinity than the primary antibody lead can be isolated.
  • the coding sequences of the scFv leads may be mutagenized by using a wide variety of methods.
  • methods of mutagenesis include, but are not limited to site-directed mutagenesis, error-prone PCR mutagenesis, cassette mutagenesis, random PCR mutagenesis, DNA shuffling, and chain shuffling.
  • Site-directed mutagenesis or point mutagenesis may be used to gradually change the V H and V sequences in specific regions. This is generally accomplished by using oligonucleotide-directed mutagenesis. For example, a short sequence of a scFv antibody lead may be replaced with a synthetically mutagenized oligonucleotide. The method may not be efficient for mutagenizing large numbers of V H and V L sequences, but may be used for fine toning of a particular lead to achieve higher affinity toward a specific target protein. Cassette mutagenesis may also be used to mutagenize the V H and V L sequences in specific regions.
  • a sequence block, or a region, of a single template is replaced by a completely or partially randomized sequence.
  • the maximum information content that can be obtained may be statistically limited by the number of random sequences of the oligonucleotides. Similar to point mutagenesis, this method may also be used for fine toning of a particular lead to achieve higher affinity toward a specific target protein.
  • Error-prone PCR or "poison" PCR
  • VH and V sequences may be used to the VH and V sequences by following protocols described in Caldwell and Joyce (1992) PCR Methods and Applications 2:28-33. Leung, D. W. et al. (1989) Technique 1 :11-
  • Figure 4 illustrates an example of the method of the present invention for affinity maturation of antibody leads selected from the primary scFv library.
  • the coding sequences of the scFv leads selected from clones containing the primary scFv library are mutagenized by using a poison PCR method. Since the coding sequences of the scFV library are contained in the expression vectors isolated from the selected clones, one or more pairs of PCR primers may be used to specifically amplify the VH and V region out of the vector. The PCR fragments containing the VH and VL sequences are mutagenized by the poison PCR under conditions that favors incorporation of mutations into the product.
  • Such conditions for poison PCR may include a) high concentrations of Mn 2+ (e.g. 0.4-0.6 mM) that efficiently induces malfunction of Taq DNA polymerase; and b) disproportionally high concentration of one nucleotide substrate (e.g., dGTP) in the PCR reaction that causes incorrect incorporation of this high concentration substrate into the template and produce mutations. Additionally, other factors such as, the number of PCR cycles, the species of DNA polymerase used, and the length of the template, may affect the rate of mis-incorporation of "wrong" nucleotides into the PCR product.
  • kits may be utilized for the mutagenesis of the selected scFv library, such as the "Diversity PCR random mutagenesis kit" (catalog No. K1830-1, Clontech, Palo Alto, CA).
  • the PCR primer pairs used in mutagenesis PCR may preferably include regions matched with the homologous recombination sites in the expression vectors. This design allows re-introduction of the PCR products after mutagenesis back into the yeast host strain again via homologous recombination. This also allows the modified VH and VL region to be fused with the AD domain directly in the expression vector in the yeast.
  • the mutagenized scFv fragments are inserted into the expression vector containing an AD domain via homologous recombination in haploid cells of ⁇ type yeast strain.
  • the AD-scFv containing haploid cells are mated with haploid cells of opposite mating type (e.g. a type) that contains the BD-Target vector and the reporter gene construct.
  • the parental diploid cells are selected based on expression of the reporter gene and other selection criteria as described in detail in Section 5.
  • PCR-based mutagenesis method can also be used, alone or in conjunction with the poison PCR described above.
  • the PCR amplified VH and VL segments may be digested with DNase to create nicks in the double DNA strand. These nicks can be expanded into gaps by other exonucleases such as Bal 31. The gaps may be then be filled by random sequences by using DNA Klenow polymerase at low concentration of regular substrates dGTP, dATP, dTTP, and dCTP with one substrate (e.g., dGTP) at a disproportionately high concentration. This fill-in reaction should produce high frequency mutations in the filled gap regions.
  • These method of DNase I digestion may be used in conjunction with poison PCR to create highest frequency of mutations in the desired VH and VL segments.
  • the PCR amplified VH and VL segments or the scFv segments amplified from the primary antibody leads may be mutagenized in vitro by using DNA shuffling techniques described by Stemmer (1994) Nature 370:389-391 ; and
  • V H , V L or scFV segments from the primary antibody leads are digested with DNase I into random fragments which are then reassembled to their original size by homologous recombination in vitro by using PCR methods.
  • the VH , VL or scFv segments amplified from the primary antibody leads may also be mutagenized in vivo by exploiting the inherent ability of mution in pre-B cells.
  • V H and V L gene segments may be cloned into a mammalian expression vector that contains human Ig enhancer and promoter. This construct may be introduced into a pre-B cell line, such as 38B9, which allows the mutation of the VH and V gene segments naturally in the pre-B cells. Liu, X., and Van Ness, B. (1999) Mol. Immunol. 36:461-469.
  • VH and V segments can be amplified from the cultured pre-B cell line and re- introduced back into the AD-containing yeast strain via, for example, homologous recombination.
  • the secondary antibody library produced by mutagenesis in vitro (e.g. PCR) or in vivo, i.e., by passing through a mammalian pre-B cell line may be cloned into an expression vector and screened against the same target protein as in the first round of screening using the primary antibody library.
  • the expression vectors containing the secondary antibody library may be transformed into haploid cells of ⁇ type yeast strain. These ⁇ cells are mated with haploid cells a type yeast strain containing the BD-target expression vector and the reporter gene construct.
  • the positive interaction of scFvs from the secondary antibody library is screened by following similar procedures as described for the selection of the primary antibody leads in yeast.
  • the secondary antibody library may be relatively low in complexity (e.g.,10 4 -10 5 independent clones) as compared to the primary libraries (e.g.,10 7 -10 14 ), the screening of the secondary antibody library may be performed without mating between two yeast strains. Instead, the linearized expression vectors containing the AD domain and the mutagenized VH and VL segments may be directly co-transformed into yeast cells containing the BD- target expression vector and the reporter gene construct. Via homologous recombination in yeast, the secondary antibody library are expressed by the recombined AD-scFv vector and screened against the target protein expressed by the BD-target vector by following similar procedures as described for the selection of the primary antibody leads in yeast.
  • the library of scFv fusion protens that are generated and selected in the screening against the target protein(s) may be expressed in hosts after the VH and V L sequences are operably linked to an expression control DNA sequence, including naturally-associated or heterologous promoters, in an expression vector.
  • the VH and VL coding sequences are positioned to ensure the transcription and translation of these inserted sequences.
  • the expression vector may be replicable in the host organism as episomes or as an integral part of the host chromosomal DNA.
  • the expression vector may also contain selection markers such as antibiotic resistance genes (e.g. neomycin and tetracycline resistance genes) to permit detection of those cells transformed with the expression vector.
  • the expression vector may be a eukaryotic vector capable of transforming or transfecting eukaryotic host cells.
  • the expression vector Once the expression vector has been incorporated into the appropriate host cells, the host cells are maintained under conditions suitable for high level expression of the single- chains polypeptide encoded by a scFv.
  • the polypeptides expressed are collected and purified depending on the expression system used.
  • the scFv, Fab, or fully assembled antibodies selected by using the methods of the present invention may be expressed in various scales in any host system such as bacteria (e.g. E. coli), yeast (e.g. S. cerevisiae), and mammalian cells (COS).
  • the bacteria expression vector may preferably contain the bacterial phage T7 promoter and express a single chain variable fragment (scFv).
  • the yeast expression vector may contain a constitutive promoter (e.g. ADGI promoter) or an inducible promoter such as (e.g. GCN4 and Gal 1 promoters). All three types of antibody, scFv, Fab, and full antibody, may be expressed in a yeast expression system.
  • the expression vector may be a mammalian express vector that can be used to express the single-chains polypeptide encoded by VH and VL in mammalian cell culture transiently or stably.
  • mammalian cell lines that may be suitable of secreting immunoglobulins include, but are not limited to, various COS cell lines, HeLa cells, myeloma cell lines, CHO cell lines, transformed B-cells and hybridomas.
  • a mammalian expression vector includes certain expression control sequences, such as an origin of replication, a promoter, an enhancer, as well as necessary processing signals, such as ribosome binding sites, RNA splice sites, polyadenylation sites, and transcriptional terminator sequences.
  • promoters include, but are not limited to, insulin promoter, human cytomegalovirus (CMV) promoter and its early promoter, simian virus SV40 promoter, Rous sarcoma virus LTR promoter/enhancer, the chicken cytoplasmic ⁇ -actin promoter, promoters derived from immunoglobulin genes, bovine papiUoma virus and adenovirus.
  • Enhancers are cis-acting sequences of between 10 to 300 bp that increase transcription by a promoter. Enhancers can effectively increase transcription when positioned either 5' or 3' to the transcription unit. They may also be effective if located within an intron or within the coding sequence itself. Examples of enhancers include, but are not limited to, SV40 enhancers, cytomegalovirus enhancers, polyoma enhancers, the mouse immunoglobulin heavy chain enhancer, and adenovirus enhancers.
  • the mammalian expression vector may also typically include a selectable marker gene.
  • suitable markers include, but are not limited to, the dihydrofolate reductase gene (DHFR), the thymidine kinase gene (TK), or prokaryotic genes conferring antibiotic resistance.
  • DHFR dihydrofolate reductase gene
  • TK thymidine kinase gene
  • prokaryotic genes conferring antibiotic resistance.
  • the DHFR and TK genes prefer the use of mutant cell lines that lack the ability to grow without the addition of thymidine to the growth medium. Transformed cells can then be identified by their ability to grow on non-supplemented media.
  • prokaryotic drug resistance genes useful as markers include genes conferring resistance to G418, mycophenolic acid and hygromycin.
  • the expression vectors containing the scFv sequences can then be transferred into the host cell by methods known in the art, depending on the type of host cells.
  • transfection techniques include, but are not limited to, calcium phosphate transfection, calcium chloride transfection, lipofection, electroporation, and microinjection.
  • VH and V sequences may also be inserted into a viral vector such as adenoviral vector that can replicate in its host cell and produce the polypeptide encoded by V H and V L in large amounts.
  • a viral vector such as adenoviral vector that can replicate in its host cell and produce the polypeptide encoded by V H and V L in large amounts.
  • the scFv, Fab, or fully assembled antibody may be expressed in mammalian cells by using a method described by Persic et al. (1997) Gene, 187:9-18.
  • the mammalian expression vector that is described by Persic and contains EF- ⁇ promoter and SV40 replication origin is preferably utilized.
  • the SV40 origin allows a high level of transient expression in cells containing large T antigen such as COS cell line.
  • the expression vector may also include secretion signal and different antibiotic markers (e.g. neo and hygro) for integration selection.
  • polypeptides encoded by VH and V may be isolated and purified by using standard procedures of the art, including ammonium sulfate precipitation, fraction column chromatography, and gel electrophoresis. Once purified, partially or to homogeneity as desired, the polypeptides may then be used therapeutically or in developing, performing assay procedures, immunofluorescent stainings, and in other biomedical and industrial applications.
  • the antibodies generated by the method of the present invention may be used for diagnosis and therapy for the treatment of various diseases such as cancer, autoimmune diseases, or viral infections.
  • the scFv human antibody with V ⁇ and VL segments that are generated and screened by using the methods of the present invention may be expressed directly in yeast. According to this embodiment, the
  • VH and V regions from the selected expression vectors may be PCR amplified with primers that simultaneously add appropriate homologous recombination sequences to the PCR products. These PCR segments of VH and VL may then be introduced into a yeast strain together with a linearized expression vector containing desirable promoters, expression tags and other transcriptional or translational signals.
  • the PCR segments of VH and VL regions may be homologously recombined with a yeast expression vector that already contains a desirable promoter in the upstream and stop codons and transcription termination signal in the downstream.
  • the promoter may be a constitutive expression promoter such as ADH1 , or an inducible expression promoter, such as Gal 1 , or GCN4 (A. Mimran, I. Marbach, and D. Engelberg, (2000) Biotechniques 28:552-560).
  • the latter inducible promoter may be preferred because the induction can be easily achieved by adding 3-AT into the medium.
  • the yeast expression vector to be used for expression of the scFv antibody may be of any standard strain with nutritional selection markers, such as His 3, Ade 2, Leu 2, Ura 3, Trp 1 and Lys 2.
  • the marker used for the expression of the selected scFv may preferably be different from the AD vector used in the selection of scFv in the two-hybrid system. This may help to avoid potential carryover problem associated with multiple yeast expression vectors.
  • the expression vector may include a secretion signal in the 5' end of the VH and V L segments, such as an alpha factor signal and a 5-pho secretion signal.
  • a secretion signal in the 5' end of the VH and V L segments, such as an alpha factor signal and a 5-pho secretion signal.
  • Certain commercially available vectors that contain a desirable secretion signal may also be used (e.g., pYEX-S1 , catalog # 6200-1 , Clontech, Palo Alto, CA).
  • the scFv antibody fragments generated may be analyzed and characterized for their affinity and specificity by using methods known in the art, such as ELISA, western, and immune staining.
  • scFv antibody fragments with reasonably good affinity with dissociation constant preferably lower than 10 "6 M) and specificity can be used as building blocks in Fab expression vectors, or can be further assembled with the constant region for full length antibody expression.
  • These fully assembled human antibodies may also be expressed in yeast in a secreted form.
  • the VH sequence encoding the selected scFv protein may be linked with the constant regions of a full antibody, C H 1 , CH2 and CH3.
  • the VL sequence may be linked with the constant region CL.
  • the assembly of two units of V H -CH1 -CH2-CH3 and V L -CL leads to formation of a fully functional antibody!
  • the present invention provides a method for producing fully functional antibody in yeast. Fully functional antibody retaining the rest of the constant regions may have a higher affinity (or avidity) than a scFv or a Fab.
  • the full antibody should also have a higher stability, thus allowing more efficient purification of antibody protein in large scale.
  • the method is provided by exploiting the ability of yeast cells to uptake and maintain multiple copies of plasmids of the same replication origin.
  • different vectors may be used to express the heavy chain and light chain separately, and yet allows for the assembly of a fully functional antibody in yeast.
  • This approach has been successfully used in a two-hybrid system design where the BD and AD vectors are identical in backbone structure except the selection markers are distinct.
  • This approach has been used in a two-hybrid system design for expressing both BD and AD fusion proteins in the yeast.
  • the BD and AD vectors are identical in their backbone structures except the selection markers are distinct. Both vectors can be maintained in yeast in high copy numbers. Chien, C. T., et al.
  • the two-hybrid system a method to identify and clone genes for proteins that interact with a protein of interest" Proc. Natl. Acad. Sci. USA 88:9578-9582.
  • the heavy chain gene and light chain genes are placed in two different vectors. Under a suitable condition, the V H -C H 1 -CH2-CH3 and V L -CL sequences are expressed and assembled in yeast, resulting in a fully functional antibody protein with two heavy chains and two light chains. This fully functional antibody may be secreted into the medium and purified directly from the supernatant.
  • the scFv with a constant region, Fab, or fully assembled antibody can be purified using methods known in the art.
  • Conventional techniques include, but are not limited to, precipitation with ammnonium sulfate and/or caprylic acid, ion exchange chromatography (e.g. DEAE), and gel filtration chromatography.
  • DEAE ion exchange chromatography
  • gel filtration chromatography e.g. DEAE
  • Delves (1997) "Antibody Production: Essential Techniques", New York, John Wiley & Sons, pages 90-113.
  • Affinity-based approaches using affinity matrix based on Protein A, Protein G or Protein L may be more efficiency and results in antibody with high purity.
  • Protein A and protein G are bacterial cell wall proteins that bind specifically and tightly to a domain of the Fc portion of certain immunoglobulins with differential binding affinity to different subclasses of IgG.
  • Protein G has higher affinities for mouse lgG1 and human lgG3 than does Protein A.
  • the affinity of Protein A of lgG1 can be enhanced by a number of different methods, including the use of binding buffers with increased pH or salt concentration.
  • Protein L binds antibodies predominantly through kappa light chain interactions without interfering with the antigen-binding site. Chateau et al. (1993) "On the interaction between Protein L and immunoglobulins of various mammalian species" Scandinavian J. Immunol.,
  • Protein L has been shown to bind strongly to human kappa light chain subclasses I, III and IV and to mouse kappa chain subclasses I.
  • Protein L can be used to purify relevant kappa chain-bearing antibodies of all classes (IgG, IgM, IgA, IgD, and IgE) from a wide variety of species, including human, mouse, rat, and rabbit.
  • Protein L can also be used for the affinity purification of scFv and Fab antibody fragments containing suitable kappa light chains.
  • Protein L-based reagents is commercially available from Actigen, Inc., Cambridgem, England. Actigen can provide a line of recombinant Protein products, including agarose conjugates for affinity purification and immobilized forms of recombinant Protein L and A fusion protein which contains four protein
  • a antibody-binding domains and four protein L kappa-binding domains are identical to each other.
  • affinity matrix may also be used, including those that exploit peptidomimetic ligands, anti-immunoglobulins, mannan binding protein, and the relevant antigen.
  • Peptidomimetic ligands resemble peptides but they do not correspond to natural peptides. Many of Peptidomimetic ligands contain unnatural or chemically modified amino acids.
  • peptidomimetic ligands designed for the affinity purification of antibodies of the IGA and IgE classes are commercially available from Tecnogen, Piana di Monte Verna, Italy.
  • Mannan binding protein (MBP) is a mannose- and N-acetylglucosamine- specific lectin found in mammalian sera. This lectin binds IgM.
  • MBP- agarose support for the purification IgM is commercially available from Pierce. Immunomagnetic methods that combine an affinity reagent (e.g. protein
  • a or an anti-immunoglobulin) with the ease of separation conferred by paramagnetic beads may be used for purifying the antibody produced.
  • Magnetic beads coated with Protein or relevant secondary antibody may be commercially available from Dynal, Inc., NY; Bangs Laboratories, Fishers, IN; and Cortex Biochem Inc., San Leandro, CA.
  • yeast is more of an ideal system for expressing human proteins than bacteria or other lower organisms. It is more likely that yeast will make the scFv, Fab, or fully assembled antibody in a correct conformation (folded correctly), and will add post-translation modifications such as correct disulfide bond(s) and glycosylations.
  • yeast has been explored for expressing many human proteins in the past. Many human proteins have been successfully produced from the yeast, such as human serum albumin (Kang, H. A. et al. (2000) Appl. Microbiol.
  • Yeast has fully characterized secretion pathways. The genetics and biochemistry of many if not all genes that regulate the pathways have been identified. Knowledge of these pathways should aid in the design of expression vectors and procedures for isolation and purification of antibody expressed in the yeast.
  • yeast has very few secreted proteases. This should keep the secreted recombinant protein quite stable.
  • yeast since yeast does not secrete many other and/or toxic proteins, the supernatant should be relatively uncontaminated. Therefore, purification of recombinant protein from yeast supernatant should be simple, efficient and economical.
  • yeast cells have a relatively thick cell wall that is not present in either bacterial or mammalian cells, the yeast cells can still keep the yeast strain growing with the yeast cell wall striped from the cells. By growing the yeast strain in yeast cells without the cell wall, secretion and purification of recombinant human antibody may be made more feasible and efficient.
  • compositions, kits and methods provided by the present invention should be very useful for selecting proteins such as human antibodies with high affinity and specificity against a wide variety of targets including, but not limited to, soluble proteins (e.g. growth factors, cytokines and chemokines), membrane-bound proteins (e.g. cell surface receptors), and viral antigens.
  • soluble proteins e.g. growth factors, cytokines and chemokines
  • membrane-bound proteins e.g. cell surface receptors
  • viral antigens e.g. viral antigens.
  • the whole process of library construction, functional screening and expression of highly diverse repertoire of human antibodies can be streamlined, and efficiently and economically performed in yeast in a high throughput and automated manner.
  • the selected proteins can have a wide variety of applications. For example, they can be used in therapeutics and diagnosis of diseases including, but not limited to, autoimmune diseases, cancer, transplant rejection, infectious diseases and inflammation.
  • a human scFv library was constructed in a yeast two-hybrid vector pACT2 that contains sequence encoding Gal4 activation domain (AD) (Li et al.
  • V H variable regions of heavy
  • V L light chain
  • Such assembled PCR products were cloned into pACT2 by homologous recombination (Hua et al, 1997) in yeast cells (MAT a strains Y187 or MaV203) (Harper et al, (1993) "The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases" Cell 75:805-16; Vidal et al. (1996) “Reverse two-hybrid and one-hybrid systems to detect dissociation of protein-protein and DNA-protein interactions” Proc Natl Acad Sci U S A. 93:10315-10320).
  • Such derived human scFvs are fused in-frame with the Gal4 activation domain.
  • a total of 5x10 7 independent yeast colonies were harvested and stored at -80 °C. More specifically, poly A + RNA from human bone marrow, human fetal liver, human spleen and human peripheral blood leukocytes were purchased from Clontech Laboratories (Palo Alto, CA). First strand cDNA were made from the poly A + RNA using random primer and PowerScript reverse transcriptase kit (Clontech Laboratories, Palo Alto, CA). A set of oligonucleotides designed by Sblattero and Bradbury (Sblattero and Bradbury (1998) "A definitive set of oligonucleotide primers for amplifying human V regions" Immunotechnology.
  • VH heavy chain variable region
  • V L light chain variable region
  • V H -linker-V L cassettes were flanked by 60 base pairs (bp) at its 5' end and 57 bp at its 3' end of sequence homologous to the sequence adjacent to multiple cloning site of the yeast two-hybrid vector pACT2 (Hua et al, (1997), supra, Hua et al (1998), supra).
  • the 5' (1.3. a) and 3' homologous sequence (1.3.b) are as follows:
  • MaV203 (MAT ⁇ , ura3-52, his3 ⁇ 200, ade2-101, trp1 ⁇ 901, leu2-3, 112, cyh2 R , can1 R , gal4 ⁇ , gai80 ⁇ , GAL1::lacZ, HIS3 UASG AU::HIS3@LYS2, SPAL10::URA3) (Vidal et al. (1996) "Reverse two-hybrid and one-hybrid systems to detect dissociation of protein-protein and DNA-protein interactions" Proc Natl Acad Sci U S A. 93:10315-10320).
  • the transformants were plated on yeast synthetic medium lacking leucine (SD/-L) and incubated at 30 °C for 2 days. A total of approximately 5x10 7 independent colonies of the yeast two-hybrid scFv library were harvested and stored at -80 °C.
  • Peptide fragments derived from human CCR5 were used as target peptides against which the scFv library constructed above was screened.
  • Three extracellular domains of human CCR5 cDNA, an N-terminal fragment, the 4 th loop (or loop 4) and the 6 th loop (or loop 6), were separately PCR-amplified from human leukocyte cDNA (Clontech Laboratories, Inc., Palo Alto, CA) using the following oligonucleotide primers.
  • the primer pair are:
  • Primer 13.13.L corresponds to the N-terminus of CCR5, with an Eco R1 site added.
  • Primer 13.13.M complements the sequence at the end of N- terminal extracellular domain (aa 36) of CCR5, with Bam HI and Stop codon added.
  • the primer pair are:
  • Primer 13.13.N corresponds the sequence at the N-terminus of 4 th loop of CCR5 (aa 167), with Eco Rl site added.
  • Primer 13.13.0 complements the sequence at the C-terminus of 4 th loop of CCR5 (aa 198), with Bam HI and Stop codon added.
  • the primer pair are:
  • Primer 13.13.P corresponds the sequence at the N-terminus of 6 th loop of hCCR5 (aa 262) at the Eco Rl site.
  • Primer 13.13.Q complements the sequence at the C-terminus of 6 th loop of CCR5 (aa 290), with Bam HI and Stop codon added.
  • PCR product of each of the domains was cloned into an Eco Rl/Bam Hl-digested cloning vector pGBKT7 (Clontech Laboratories, Palo Alto, CA) with the Gal4 DNA binding domain (DNA-BD) at its carboxy terminus.
  • the resulting plasmids were designated as follows:
  • pG90 pGBKT7-CCR5 N-terminus
  • pG91 pGBKT7-CCR5 loop 4
  • pG92 pGBKT7-CCR5 loop 6.
  • yeast strain AH109 MATa, ura3-52, his3-200, ade2-101, trpl- 901, Ieu2-3,112, ga!4 A, gal80A, LYS2::GAL1 ⁇ AS -GAL1 ⁇ AT -HIS3, GAL2 ⁇ AS - GAL2TA TA -ADE2, (Clontech Laboratories, Palo
  • the AH109 transformants containing one of the three extracellular domains were mated with MAT ⁇ type yeast cells (Y187 or MaV203 strain) containing the scFv library following the protocols from Clontech Laboratories.
  • the scFv library-containing vector pACT2 contains a LEU2 gene, whereas the pGBKT7 plasmids contain a TRP1 gene. Cells harboring both plasmids can grow in the yeast synthetic medium lacking leucine and tryptophan (SD/-LW).
  • pGBKT7 plasmids encoding CCR5 domains empty vector pGBKT7 and pGBKT7-Lam (Clontech) (which contains sequence of human lamin C), were co-transformed, respectively, with individual scFv plasmids into yeast cells, followed by growth selection on SD/-LW or SD/-AHLW media. Yeast colonies grown on the selection media were subjected to ⁇ - galactosidase activity assays. The sequences of those scFv clones specific to human CCR5 domains were determined with an ABI automatic sequencer.
  • ScFv clones 15.150.11 and 15.150.12 were cloned into E. coli expression vector pET27b(+) (Novagen) to facilitate expression of scFv antibodies of Ab32 and Ab33, respectively.
  • ScFv proteins were expressed and purified from the periplasmic space of the bacteria.
  • the ability of the selected anti-CCR5 scFv antibodies, Ab32 and Ab33, to inhibit HIV-1 infection was determined by using an assay described in Cotter et al. (2001) J. Virol. 75:4308- 4320.
  • the control scFv antibody used was anti-human p53 scFv antibody.
  • Human monocytes were recovered from peripheral blood mononuclear cells of HIV-1 -, HIV-2-, and hepatitis B virus-seronegative donors after leukapheresis and then purified by countercurrent centrifugal elutriation. Monocytes were cultured as adherent monolayers and differentiated for 7 days into macrophages (monocyte-derived macrophages or MDM). MDM were first incubated with different concentrations of scFv antibodies, then infected with
  • HIV-1 reverse transcriptase activity was determined at Day 4, Day 8 and Day 12, as incorporation of [ 3 H]TTP (Cotter et al, 2001 , J. Virol. 75:4308- 4320).
  • Radiolabeled nucleotides were precipitated with cold 10% trichloroacetic acid on paper filters in an automatic cell harvester and washed with 95% ethanol. Radioactivity was estimated by liquid scintillation spectroscopy.
  • the cell viability was determined by MTT assay. Briefly, MTT (3- ⁇ 4,5- Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide, from Sigma) was dissolved in cell culture medium without phenol red. Live cells will convert MTT into purple dye inside cells. The dye was solubilized with acidic isopropanol and absorbance (OD) of the converted dye was measured at 570 nm.
  • Figures 9A-C show HIV-1 RT activity in monocytes infected by HIV-1 in the presence or absence of two selected scFv antibodies against human CCR5 Loop (Ab32 and AB33) of the present invention on day 4, 8, and 12 post infection, respectively.
  • both Ab32 and AB33 effectively inhibit HIV-1 RT activity at concentrations 20, 2.0 and 0.2 ⁇ g/mL.
  • a non-specific antibody which is elicited against the tumor suppressor p53 protein), Ab 16 is completely ineffective in inhibition of HIV-1 RT activity.
  • the positive control a murine monoclonal antibody 2D7 (available from Pharmingen, San Diego, CA) could inhibit HIV-1 RT activity at a concentration of 10 ⁇ g/mL.
  • a murine monoclonal antibody 2D7 available from Pharmingen, San Diego, CA
  • RT activity is completely uninhibited. Throughout the incubation period, the HIV- infected monocytes had normal viability in the presence or absence of these antibodies, as shown in Figures 10A-C.
  • FIGS 11A-C show HIV-1 RT activity in monocytes infected by HIV-1 in the presence or absence of Ab32 and AB33 at various concentrations on day 4, 8, and 12 post infection, respectively.
  • a concentration as lower as 0.02 ⁇ g/mL ( ⁇ 0.8 nM) both Ab32 and AB33 could inhibit HIV-1 RT activity by 75% on day 12 post infection of the monocytes.
  • the ability of the human monoclonal scFv antibodies Ab32 and Ab33 to bind with their target protein was confirmed by Western blot. Briefly, lysate of human macrophage (expressing CCR5) was separated on SDS-PAGE, and transferred to nitrocellulose membrane. The membrane was then probed either with the scFv selected in the above-described process (Ab32 and Ab33 ) or positive control antibody (murine monoclonal antibody 2D7 from Pharmingen, San Diego), or a negative control (Ab16, an anti-p53 scFv antibody). The positive control (MAb 2D7) blot was then probed with goat anti-mouse IgG conjugated with HRP (horse radish peroxidase).
  • FIG. 12 shows the Western blot of CCR5 expressed by human macrophage probed by Ab32 and Ab33. As shown in Figure 12, both Ab32 and Ab33 were capable of binding to CCR5, just like the positive control MAb 2D7. In contrast, a non-specific scFv antibody elicited against human p53 protein, AB16, is incapable of binding to CCR5.
  • the human monoclonal scFv antibodies Ab32 and Ab33 effectively blocked the binding of 125 l MIP1- ⁇ to its cognate receptor CCR5 on human MDMs.
  • both Ab32 and Ab33 exhibited slightly stronger binding affinity to human CCR5 than the mouse monoclonal antibody
  • non-labeled MIP1- ⁇ was used to compete with 125 I MIP1- ⁇ for binding to CCR5.
  • MIP1- ⁇ could compete with 125 l MIP1- for binding to CCR5 at a concentration of 25 nm.
  • another cognate ligand of human CCR5 RANTES, could also compete with 1 5 l MIP1- ⁇ for binding to CCR5 at a concentration of 25 nm.
  • the last extracellular loop of human CXCR4, loop 6 was used as the target peptide fragment for eliciting monoclonal antibodies against CXCR4 in yeast.
  • the cDNA encoding CXCR4 loop 6 was amplified from human leukocyte Quick-clone cDNA (purchased from BD-Clontech, Cat. # 7182-1) using primers 13.12.G and 13.12.H.
  • the PCR product was cloned into Eco Rl / Bam HI sites of pGBK-T7 , resulting a plasmid (designated as pG88) encoding CXCR4 loop 6 with the Gal4 DNA binding domain fused at its carboxy terminus.
  • the DNA sequence of the coding region of human CXCR4 loop ⁇ is as follows:
  • amino acid sequence encoded by the above DNA sequence is as follows:
  • Plasmid DNA of pG88 was transformed into yeast cells of strain AH109. Transformed cells were mated with a fully human scFv library as described in Section 1 of "EXAMPLE" above. The mated cells were selected on medium SD/-Leu-Trp-His-Ade. Cells grown on the selection medium were assayed for ⁇ -gal activities. Non-specific scFv clones were ruled out by assaying with control bait plasmids (pGBK-T7 and pGBK-Lam). DNA sequences of the scFv inserts from the human CXCR4 loop 6-specific clones were determined. Two clones with complete scFv inserts were obtained. These two scFv clones were designated Ab124 and Ab125. Their nucleotide and amino acid sequences are listed in Figure 15.
  • the selected antibodies were tested for their ability to inhibit SDF-1 induced chemotaxis in MDA-MB-231 cells.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne des procédés de criblage efficaces à haut rendement de banques d'anticorps dirigés contre des cibles protéiques, notamment des protéines membranaires. Cette invention concerne plus particulièrement des procédés de criblage d'une banque d'anticorps entièrement humains dirigés contre des protéines membranaires telles que des récepteurs de la chimiokine dans des levures. De manière plus particulière, on crible une banque d'anticorps monocaténaires humains dirigés contre des fragments peptidiques dérivés respectivement de domaines extracellulaires de CXCR4 et CCR5 humains et on sélectionne des anticorps monoclonaux à haute affinité dirigés contre CXCR4 et CCR5. Ces anticorps peuvent être utilisés en tant qu'agents prophylactiques ou thérapeutiques pour prévenir et traiter l'infection par le VIH, le cancer et d'autres maladies ou pathologies, ainsi que pour cribler des médicaments et diagnostiquer des maladies ou des pathologies associées aux interactions avec les protéines membranaires.
PCT/US2003/003763 2002-02-08 2003-02-07 Anticorps monoclonaux humains diriges contre des proteines membranaires WO2003066830A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003209059A AU2003209059A1 (en) 2002-02-08 2003-02-07 Human monoclonal antibodies against membrane proteins

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US10/071,866 2002-02-08
US10/072,031 2002-02-08
US10/071,866 US20030165988A1 (en) 2002-02-08 2002-02-08 High throughput generation of human monoclonal antibody against peptide fragments derived from membrane proteins
US10/072,031 US6766082B2 (en) 2000-10-18 2002-02-08 Waveguide-type optical device and manufacturing method therefor
US13397802A 2002-04-25 2002-04-25
US10/133,978 2002-04-25

Publications (2)

Publication Number Publication Date
WO2003066830A2 true WO2003066830A2 (fr) 2003-08-14
WO2003066830A3 WO2003066830A3 (fr) 2009-06-18

Family

ID=27738990

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/003763 WO2003066830A2 (fr) 2002-02-08 2003-02-07 Anticorps monoclonaux humains diriges contre des proteines membranaires

Country Status (2)

Country Link
AU (1) AU2003209059A1 (fr)
WO (1) WO2003066830A2 (fr)

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006068646A1 (fr) * 2004-12-20 2006-06-29 Xiaoming Chen Méthodes d'identification et d'isolement d'anticorps spécifiques d'un épitope
WO2006089141A2 (fr) * 2005-02-18 2006-08-24 Dana-Farber Cancer Institute Anticorps contre cxcr4 et leurs procédés d'utilisation
WO2006103100A2 (fr) 2005-04-01 2006-10-05 F. Hoffmann-La Roche Ag Anticorps anti-ccr5 et utilisations associees
WO2008019817A1 (fr) 2006-08-17 2008-02-21 F. Hoffmann-La Roche Ag Conjugué d'un anticorps dirigé contre le ccr5 et peptide antifusiogène
WO2008037419A1 (fr) 2006-09-29 2008-04-03 F. Hoffmann-La Roche Ag Anticorps dirigés contre le ccr5 et ses utilisations
WO2008110332A1 (fr) 2007-03-13 2008-09-18 F.Hoffmann-La Roche Ag Conjugués de complément peptidique
WO2009138519A1 (fr) * 2008-05-16 2009-11-19 Ablynx Nv Séquences d'acides aminés dirigées contre cxcr4 et autres gpcr et composés renfermant ces dernières
WO2010021697A3 (fr) * 2008-08-18 2010-09-16 Pfizer Inc. Anticorps anti-ccr2
US7892546B2 (en) 2008-05-14 2011-02-22 Eli Lilly And Company Anti-CXCR4 antibodies
US7951920B2 (en) 2006-08-17 2011-05-31 Roche Palo Alto Llc Conjugate of an antibody against CCR5 and an antifusogenic peptide
CN102323423A (zh) * 2011-05-31 2012-01-18 昆明理工大学 检测曲妥珠影响MCF-7细胞中Trx-1蛋白表达的方法
WO2013024022A1 (fr) 2011-08-12 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques pour traiter l'hypertension pulmonaire
US8628750B2 (en) 2006-02-27 2014-01-14 Technische Universitat Munchen Cancer imaging and treatment
US8748107B2 (en) 2010-02-10 2014-06-10 Affitech Research As Isolated antibodies which bind to CXC chemokine receptor 4
WO2014144725A2 (fr) * 2013-03-15 2014-09-18 Salimetrics, Llc Anticorps monoclonal de mélatonine, détection, procédés et utilisations de celui-ci
US8937164B2 (en) 2010-03-26 2015-01-20 Ablynx N.V. Biological materials related to CXCR7
US8969540B2 (en) * 2004-06-10 2015-03-03 Viventia Bio Inc. Tumor specific antibody
US9512236B2 (en) 2006-12-19 2016-12-06 Ablynx N.V. Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
WO2017220990A1 (fr) 2016-06-20 2017-12-28 Kymab Limited Anticorps anti-pd-l1
US9994639B2 (en) 2011-03-28 2018-06-12 Ablynx N.V. Biological materials related to CXCR7
US10041064B2 (en) 2008-12-16 2018-08-07 Novartis Ag Yeast display systems
CN112646833A (zh) * 2020-11-05 2021-04-13 杭州阿诺生物医药科技有限公司 一种全人源抗体酵母展示技术的设计与构建
WO2021222069A1 (fr) 2020-04-27 2021-11-04 Incelldx, Inc. Méthodes et compositions pour le traitement d'infections de type choc cytokinique, notamment la covd-19, par inhibition de l'interaction ccr5/ccl5
US11492383B2 (en) 2011-06-24 2022-11-08 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
WO2023016454A1 (fr) * 2021-08-12 2023-02-16 The University Of Hong Kong Matériaux et procédés pour définir de manière complète des réponses immunitaires adaptatives
CN116731165A (zh) * 2023-03-23 2023-09-12 北京巴瑞医疗器械有限公司 一种抗血清素抗体及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869250A (en) * 1996-12-02 1999-02-09 The University Of North Carolina At Chapel Hill Method for the identification of peptides that recognize specific DNA sequences
WO1999028502A1 (fr) * 1997-11-28 1999-06-10 Invitrogen Corporation Reactifs de fusion d'anticorps monoclonal a chaine unique regulant une transcription in vivo

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869250A (en) * 1996-12-02 1999-02-09 The University Of North Carolina At Chapel Hill Method for the identification of peptides that recognize specific DNA sequences
WO1999028502A1 (fr) * 1997-11-28 1999-06-10 Invitrogen Corporation Reactifs de fusion d'anticorps monoclonal a chaine unique regulant une transcription in vivo

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
UEDA M.: 'Genetic immobilization of proteins on the yeast cell surface' BIOTECHNOLOGY ADVANCES vol. 18, 2000, pages 121 - 140 *

Cited By (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8969540B2 (en) * 2004-06-10 2015-03-03 Viventia Bio Inc. Tumor specific antibody
WO2006068646A1 (fr) * 2004-12-20 2006-06-29 Xiaoming Chen Méthodes d'identification et d'isolement d'anticorps spécifiques d'un épitope
WO2006089141A2 (fr) * 2005-02-18 2006-08-24 Dana-Farber Cancer Institute Anticorps contre cxcr4 et leurs procédés d'utilisation
WO2006089141A3 (fr) * 2005-02-18 2006-12-07 Dana Farber Cancer Inst Inc Anticorps contre cxcr4 et leurs procédés d'utilisation
US8329178B2 (en) 2005-02-18 2012-12-11 Dana-Farber Cancer Institute, Inc. Antibodies against CXCR4 and methods of use thereof
WO2006103100A2 (fr) 2005-04-01 2006-10-05 F. Hoffmann-La Roche Ag Anticorps anti-ccr5 et utilisations associees
US7615216B2 (en) 2005-04-01 2009-11-10 Roche Palo Alto Llc Antibodies against CCR5 and uses thereof
US8628750B2 (en) 2006-02-27 2014-01-14 Technische Universitat Munchen Cancer imaging and treatment
US7951920B2 (en) 2006-08-17 2011-05-31 Roche Palo Alto Llc Conjugate of an antibody against CCR5 and an antifusogenic peptide
WO2008019817A1 (fr) 2006-08-17 2008-02-21 F. Hoffmann-La Roche Ag Conjugué d'un anticorps dirigé contre le ccr5 et peptide antifusiogène
WO2008037419A1 (fr) 2006-09-29 2008-04-03 F. Hoffmann-La Roche Ag Anticorps dirigés contre le ccr5 et ses utilisations
US9512236B2 (en) 2006-12-19 2016-12-06 Ablynx N.V. Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
WO2008110332A1 (fr) 2007-03-13 2008-09-18 F.Hoffmann-La Roche Ag Conjugués de complément peptidique
US8003102B2 (en) 2008-05-14 2011-08-23 Eli Lilly And Company Anti-CXCR4 antibodies
US7892546B2 (en) 2008-05-14 2011-02-22 Eli Lilly And Company Anti-CXCR4 antibodies
US9212226B2 (en) 2008-05-16 2015-12-15 Ablynx N.V. Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same
AU2009248049B2 (en) * 2008-05-16 2015-07-23 Ablynx N.V. Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same
US20110206660A1 (en) * 2008-05-16 2011-08-25 Ablynx N.V. Amino acid sequences directed against cxcr4 and other gpcrs and compounds comprising the same
WO2009138519A1 (fr) * 2008-05-16 2009-11-19 Ablynx Nv Séquences d'acides aminés dirigées contre cxcr4 et autres gpcr et composés renfermant ces dernières
CN102239180B (zh) * 2008-08-18 2014-12-31 辉瑞大药厂 抗ccr2抗体
KR101772706B1 (ko) 2008-08-18 2017-08-29 화이자 인크. Ｃｃｒ２에 대한 항체
WO2010021697A3 (fr) * 2008-08-18 2010-09-16 Pfizer Inc. Anticorps anti-ccr2
US8710191B2 (en) 2008-08-18 2014-04-29 Pfizer Inc. Antibodies to CCR2
US9238691B2 (en) 2008-08-18 2016-01-19 Pfizer Inc. Nucleic acids encoding antibodies to CCR2
CN102239180A (zh) * 2008-08-18 2011-11-09 辉瑞大药厂 抗ccr2抗体
RU2547595C2 (ru) * 2008-08-18 2015-04-10 Пфайзер Инк Антитела против ccr2
US10041064B2 (en) 2008-12-16 2018-08-07 Novartis Ag Yeast display systems
US10301616B2 (en) 2008-12-16 2019-05-28 Novartis Ag Yeast display systems
US9353185B2 (en) 2010-02-10 2016-05-31 Affitech Research As Antibodies
US8748107B2 (en) 2010-02-10 2014-06-10 Affitech Research As Isolated antibodies which bind to CXC chemokine receptor 4
US8937164B2 (en) 2010-03-26 2015-01-20 Ablynx N.V. Biological materials related to CXCR7
US9758584B2 (en) 2010-03-26 2017-09-12 Ablynx N.V. Biological materials related to CXCR7
US9994639B2 (en) 2011-03-28 2018-06-12 Ablynx N.V. Biological materials related to CXCR7
CN102323423A (zh) * 2011-05-31 2012-01-18 昆明理工大学 检测曲妥珠影响MCF-7细胞中Trx-1蛋白表达的方法
US11492383B2 (en) 2011-06-24 2022-11-08 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
WO2013024022A1 (fr) 2011-08-12 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques pour traiter l'hypertension pulmonaire
WO2014144725A2 (fr) * 2013-03-15 2014-09-18 Salimetrics, Llc Anticorps monoclonal de mélatonine, détection, procédés et utilisations de celui-ci
WO2014144725A3 (fr) * 2013-03-15 2015-01-29 Salimetrics, Llc Anticorps monoclonal de mélatonine, détection, procédés et utilisations de celui-ci
US10787512B2 (en) 2013-03-15 2020-09-29 Salimetrics, Llc Melatonin monoclonal antibody, detection, methods and uses thereof
WO2017220988A1 (fr) 2016-06-20 2017-12-28 Kymab Limited Anticorps multispécifiques pour l'immuno-oncologie
WO2017220989A1 (fr) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 et cytokines il-2
WO2017220990A1 (fr) 2016-06-20 2017-12-28 Kymab Limited Anticorps anti-pd-l1
WO2021222069A1 (fr) 2020-04-27 2021-11-04 Incelldx, Inc. Méthodes et compositions pour le traitement d'infections de type choc cytokinique, notamment la covd-19, par inhibition de l'interaction ccr5/ccl5
CN112646833A (zh) * 2020-11-05 2021-04-13 杭州阿诺生物医药科技有限公司 一种全人源抗体酵母展示技术的设计与构建
US11680271B2 (en) 2020-11-05 2023-06-20 Adlai Nortye Biopharma Co., Ltd. Construction of fully human antibody yeast display technique
WO2023016454A1 (fr) * 2021-08-12 2023-02-16 The University Of Hong Kong Matériaux et procédés pour définir de manière complète des réponses immunitaires adaptatives
CN116731165A (zh) * 2023-03-23 2023-09-12 北京巴瑞医疗器械有限公司 一种抗血清素抗体及其应用

Also Published As

Publication number Publication date
AU2003209059A1 (en) 2003-09-02
AU2003209059A8 (en) 2009-07-30
WO2003066830A3 (fr) 2009-06-18

Similar Documents

Publication Publication Date Title
US7700302B2 (en) Method for generating and selecting antibodies against target protein
WO2003066830A2 (fr) Anticorps monoclonaux humains diriges contre des proteines membranaires
US7005503B2 (en) Human monoclonal antibody against coreceptors for human immunodeficiency virus
US20030165988A1 (en) High throughput generation of human monoclonal antibody against peptide fragments derived from membrane proteins
US6723538B2 (en) Bispecific antibody and chemokine receptor constructs
EP1871807B1 (fr) Anticorps contre cxcr4 et leurs procédés d'utilisation
EP1603949B9 (fr) Anticorps diriges contre le recepteur humain de l'il-21 et utilisations correspondantes
AU2006206064B2 (en) Anti-CCR2 antibodies and methods of use therefor
US20030166870A1 (en) Anti-CCR5 antibodies and methods of use therefor
AU2009201216A8 (en) Humanized anti-CCR2 antibodies and methods of use therefor
US10273305B2 (en) Bispecific CXCR4-CD4 polypeptides with potent anti-HIV activity
WO2002000729A2 (fr) Generation et criblage a haut rendement d'un repertoire d'anticorps entierement humains dans la levure
EP3978529A1 (fr) Anticorps anti-pd-1 canin se liant à pd-1 canin
RU2252786C2 (ru) Конструкции антител и хемокинов и их применение при иммунологических нарушениях
US20050123973A1 (en) Methods for generating monoclonal antibody against fusion protein containing peptide fragment derived from membrane protein
CN110959015B (zh) 双特异性重组蛋白
CA2411515A1 (fr) Generation et criblage a haut rendement d'un repertoire d'anticorps entierement humains dans la levure
Sui et al. Identification of CD4 and transferrin receptor antibodies by CXCR4 antibody‐guided Pathfinder selection
CN112661847B (zh) 一种以巨噬细胞凋亡抑制因子为靶点的全人源拮抗抗体及其应用
CN118546249A (zh) 特异性结合TNF-α的抗体、抗体片段及其用途
CN118546250A (zh) 特异性结合IFN-α2的抗体、抗体片段及其用途

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP